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ABSTRACT 
TECHNOLOGY-DRIVEN HEART FAILURE MANAGEMENT SYSTEM: 
CHANGES IN FUNCTIONAL CAPACITY AND QUALITY OF LIFE 
Venkata S. Chilakapati 
April 14, 2010 
Background: Heart failure treatment guidelines emphasize the importance of 
daily weight monitoring. To support this practice, the Health Care Financing 
Administration Heart Failure Demonstration Project (2000) was designed to evaluate the 
effect of technology driven monitoring of daily weight and symptoms in elderly HF 
patients (NYHA class II to IV). This sub-study is conducted to assess the effect of a 
technology driven HF monitoring system on clinically meaningful change in functional 
capacity and quality oflife (QOL). 
Methods: This is a randomized, multi-centered, controlled clinical trial in which 
Medicare beneficiaries with a history of hospitalization within one year were randomized 
to standard care or standard care + a technology driven heart failure monitoring system. 
Primary end points were clinically meaningful change in functional capacity [6-minute 
walk distance (6MWD) or 6-minute work (6MW)] and QOL [Minnesota Living with 
Heart Failure Questionnaire (MLHF)] after 6-months of follow-up. Regression to the 
mean effects were estimated and adjusted according to the Edwards-Nunnally (EN) 
method. Clinically meaningful change is then defined in terms of the standard error of 
measurement (SEM) criterion. 
v 
Results: Two hundred eighty four patients from three centers in USA were 
randomized. Mean age was 74 +/- 9 yrs, 58% were male, 82% were Caucasians, and New 
York Heart Association class II (31%), III (59%), and IV (10%). The change in 
functional capacity in terms of 6WD was 42 m, by 6MW was 3668 kg/m of work, and 
change in QOL in terms ofMLHF total score by 6.0, physical dimension score by 4.0, 
and emotional dimension score by 2.0 from baseline. Body mass index, Left ventricular 
Ejection Fraction, beta-blocker usage and intra-cardiac device (leD) implantation were 
the best clinically relevant predictors of change in functional capacity. Technology 
driven heart failure management did not result in a clinically meaningful incremental 
benefit in functional capacity or in QOL. 
Conclusions: There is no significant clinically meaningful benefit in functional 
capacity or in QOL from technology driven HF monitoring system in NYHA class II-IV 
elderly HF patients. Further, monitoring HF patients increased outpatient care resource 
utilization and costs, and was associated with a significantly poorer QOL. 
VI 
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Heart failure (HF) is a clinical syndrome in which the cardiac pump fails to pump 
an adequate amount of blood to meet systemic requirements, either due to reduced 
cardiac contractility (systolic failure) or impaired cardiac relaxation and filling (diastolic 
dysfunction) or both (Johnson, Parker, & Patterson, 2002). Initially, HF triggers various 
neuro-hormonal mechanisms to compensate. However, as HF progresses, the body's 
compensatory and maladaptive mechanisms become imbalanced, which leads to clinical 
deterioration (Johnson et aI., 2002). Common signs and symptoms ofHF include fatigue, 
shortness of breath, difficulty breathing (especially at night, when lying down, or during 
physical exertion), cough, weight gain (from fluid retention), and swelling of the feet and 
ankles (National Heart, Lung, and Blood Institute [NHLBI], 2004). 
Disease Impact 
HF is a major, growing public health problem in the United States affecting 4.9 
million people (American Heart Association [AHA], 2009). Each year, 550,000 new 
cases are diagnosed (AHA, 2009). The increasing population of older Americans and the 
prolongation of the lives of cardiac patients by modem therapeutic strategies have led to 
the growing incidence ofHF (Kannel & Belanger, 1991). Among Americans aged 65 or 
older, the incidence ofHF is increasing and is approaching 1 in 100 (AHA, 2005, 2009). 
1 
HF accounts for 12 to 15 million U.S. office visits and 6.5 million hospital days 
each year, with an average length of stay of 7.7 days for each admission (0' Connell & 
Bristow, 1994). Between 1979 and 2005, hospital discharges for HF increased by 157% 
(AHA, 2005), and between 1979 and 2009, they rose by 171 % (AHA, 2009). However, 
despite advanced therapies and technology, the mortality rate ofHF remains high. The 
number of total reported deaths from HF was 287,000 in 1995 and 292,000 in 2005 
(AHA, 2009). The overall death rate for HF in 2005 was 52.3 per 100,000 (AHA, 2009). 
Moreover, HF is mentioned on the death certificate for one in eight deaths (AHA, 2009). 
In spite of the commitment to healthcare in the United States, the economic 
burden ofHF is staggering. In 2005, almost 4.8 million Americans were afflicted with 
HF, accounting for 15% of the total cost of heart disease (AHA, 2006). In 2005, the total 
direct and indirect cost ofHF in the United States was equal to $27.9 billion (AHA, 
2005), and the estimated direct and indirect cost for 2009 is $37.2 billion (AHA, 2009). 
Almost 75% of costs associated with a typical HF-related hospitalization accumulate 
within the first 48 hours (O'Connell & Bristow, 1994). Hospital charges for HF 
management are approximately $10,000 per discharge based on a mean length of stay of 
5.5 to 6.5 days (AHA, 2008). 
According to the Medicare program, Center for Medicare and Medicaid Services 
(CMS) expenditures for HF in 1991 were higher than those for cancer and those for 
myocardial infarction (Massie & Shah, 1997). HF is the most common Medicare 
diagnosis-related group (DRG), and more Medicare dollars are spent on diagnosis and 
treatment of HF than on any other diagnosis (Massie & Shah, 1997). HF costs accounted 
2 
for 37% of Medicare spending (AHA, 2008), and in 1999, Medicare reported paying $3.6 
billion for care ofHF (AHA, 2005). 
Heart Failure and Clinical Status Changes 
The severity of HF can be classified symptomatically by using a scheme such as 
the New York Heart Association's (NYHA) functional classification, which groups 
patients according to the amount of effort needed to produce HF symptoms (Criteria 
Committee NHY A, 1964, p. 114; see Table 1). 
Table 1 
NYHA Functional Classification of Heart Failure 
NYHA Metabolic 
grading Characterisitics equivalenta 
Class I No limitations. Ordinary physical activity doesn't cause >7 
undue fatigue, dyspnea, or palpitations (asymptomatic LV 
dysfunction) 
Class II Slight limitation of physical activity. Ordinary physical 5 
activity results in fatigue, palpitation, dyspnea or angina 
pectoris (mild congestive heart failure [CHF]) 
Class III Marked limitation of physical activity. Less than ordinary 2-3 
physical activity leads to symptoms (moderate CHF) 
Class IV Unable to carryon any physical activity without discomfort. 1.6 
Symptoms of CHF present at rest (severe CHF) 
aMetabolic equivalent is defined as the resting V02 for a 40-year-old 70 kg man. 1 MET 
= 3.5 ml 02/minlkg body weight. 
3 
NYHA classification is not a good prognostic indicator, because symptom 
severity can rise and fall despite constant pharmacologic and non-pharmacologic 
treatments (Hunt, Baker, & Chin, 2001). 
American Heart Association Prognostic Classification 
The staging system to define the prognosis of patients with HF was developed by 
the AHA in 1999 (Hunt et aI., 2001; see Table 2). 
Table 2 







Patients with risk factors for the development of structural heart 
disease or for the development of overt HF 
Presence of structural heart disease (e.g., myocardial infarction or 
left ventricular dysfunction) without symptoms of HF 
Patients with structural heart disease with current or prior symptoms 
of HF amenable to therapy 
HF refractory to conventional treatment requiring ventricular assist 
device, transplantation, or palliative care 
Note. Prognosis worsens if disease progresses from Stage A through D 
4 
Heart Failure and Functional Capacity 
The hallmark of HF is exercise intolerance and activity restriction most 
commonly due to impaired breathing and fatigue. These symptoms are debilitating and 
result in low functional capacity, progressive physical disability, hospitalization, medical 
management, and follow-up. Moreover, as HF advances, functional capacity 
deteri orates. 
The most popular clinical exercise tests, in order of increasing complexity, are 
stair climbing, 6-minute walk test (6MWT), shuttle-walk test, cardiac stress test (e.g., 
Bruce protocol), and cardiopulmonary exercise test (Wasserman, Hansen, Sue, Casaburi, 
& Whipp, 1999; Weisman & Zeballos, 1994). A recent review of functional walking 
tests concluded that "the 6MWT is easy to administer, better tolerated, and more 
reflective of activities of daily living than the other walk tests" (Solway, Brooks, Lacasse, 
& Thomas, 2001, p. 256). 
The 6MWT is a simple and noninvasive measure of the distance covered in 
consecutive 30-meter or 100-foot laps over a 6-minute period (American Thoracic 
Society [ATS], 2002). The ability to walk the distance strongly and independently 
predicts morbidity and mortality (Bittner et aI., 1993; Guyatt, Sullivan, et aI., 1985; 
Lipkin, Scriven, & Poole-Wilson, 1986; Poole-Wilson, 2000). However, distance 
covered doesn't take into account differences in bodyweight that are known to influence 
exercise capacity (Carter et aI., 2003). Carter et aI. stated that the 6-minute distance 
times bodyweight product (6-minute walk work expressed in kilograms per meter of 
work) is an improved outcome measure for estimating functional capacity in patients with 
chronic obstructive pulmonary disease (COPD; Carter et aI., 2003). 
5 
Heart Failure and Quality Of Life 
Poor physical condition, emotional distress, and frequent hospital admissions 
contribute to decreased quality oflife (QOL) among individuals with HF (Blyth et aI., 
1997; Cafagna, Ponte, & Burri 1 , 1997), which can lead to social impairments, depression, 
and psychological disorders (Majania et aI., 1999; Steptoe, Mohabir, Mahon, & 
McKenna, 2000). Depression has been reported in 240/0-42% of patients suffering from 
congestive HF (Havranek, Ware, & Lowes, 1999; Skotzko et aI., 2000). Vaccarino et ai. 
(2001) and Jiang et ai. (2001) found that depression reduced functional status and 
increased readmission rates and mortality in patients with CHF. Depressed patients 
required a greater number of inpatient hospital days and at 1 year, showed greater 
mortality (Freedland et aI., 1991). 
QOL deteriorates more rapidly and seriously for patients with chronic HF than for 
those with other chronic disease like arthritis and COPD (Stewart et aI., 1989). Gott et ai. 
(2006) investigated the predictors of quality of life in patients with HF and found that 
QOL for older people with HF could be described as challenging and difficult. Among 
542 people with HF under the age of 60, the following factors were predictive of reduced 
QOL: being female, being in an older age group, showing evidence of depression, being 
NYHA Class III and IV, having two or more comorbidities, and being from a low 
socioeconomic group (Gott et aI., 2006). These factors could help clinicians to identify 
those at risk of reduced QOL and appropriately target interventions. 
Poor QOL may have a negative effect on compliance with medical treatment and 
behavioral regimens (Jaarsma et aI., 1999) and, thus, result in further impairment of 
exercise tolerance, prognosis, and QOL. To interrupt this vicious cycle, an integrated and 
6 
comprehensive HF intervention program comprising adequate pharmacologic treatment 
and careful home monitoring is needed. 
Heart Failure and Clinical Management 
The standard of care for HF includes pharmacologic and non-pharmacologic 
measures. Pharmacologic management of HF includes diuretics, angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, digitalis, and 
vasodilators. Diuretics, especially loop diuretics (e.g., Furosemide), are used to promote 
the elimination of excess sodium and water by the kidneys (Brater, 1997). ACE 
inhibitors are recommended for patients with left ventricular dysfunction and have been 
shown to reduce mortality from HF; improve HF symptoms, exercise tolerance, and left 
ventricular ejection fraction; and reduce emergency room visits and hospitalizations 
(Cohn et aI., 1986; Pitt et aI., 1991; Yusuf et aI., 2000). 
Angiotensin receptor blockers may be an alternative for patients who are unable 
to tolerate ACE inhibitors (Yusuf et ai., 2003). Hydralazine and nitrates in combination 
are effective after load and preload reducing agents used in ACE-intolerant patients 
(Cohn et ai., 1991). Beta blockers have been shown to slow the progression ofHF and to 
reduce hospitalization and mortality by blocking sympathetic stimulation (Hjalmarson et 
aI., 2000; Packer et aI., 1999). Digoxin is a weak inotrope, whose main effect is 
neuroharmonal modulation; it has been shown to reduce symptoms, improve physical 
function and QOL, and decrease the rate of hospitalization in patients with HF, but has 
not been shown to have an effect on mortality (Digitalis Investigation Group, 1997). 
Inotropic agents like dobutamine or milrinone are useful in select patients with 
acute exacerbations of hypotensive HF or shock (Felker et ai., 2001). Spiranolactone, an 
7 
aldosterone antagonist, showed mortality benefit when added to standard therapy for 
patients with HF (in NYHA Classes III-IV; Pitt et aI., 1999). Intravenous nitroglycerin 
or nitroprusside are recommended for the management of patients with acute pulmonary 
edema ("ACC/ AHA Guidelines," 2001). 
Patients with HF are more prone to sudden cardiac death. Internal cardioverter 
defibrillators (lCDs) improve longevity for survivors of cardiac arrest; patients with 
sustained ventricular tachycardia, inducible ventricular tachycardia, and left ventricular 
ejection fraction (LVEF) less than 30% following a myocardial infarction (Gollob & 
Seger, 2002; Moss, Zareba, Hall, Klein, & Wilber, 2002); and dilated cardiomyopathy 
patients with LVEF < 30% and NYHA Class II (Kadish et aI., 2004). 
Left ventricular assist devices (LV AD) are used for patients with cardiogenic 
shock who are unresponsive to inotropic therapy and intra-aortic balloon counter 
pulsation, or they may be used as a bridge therapy for patients with cardiac 
transplantation (Delgado et aI., 2002; Rose et aI., 2001). Cardiac transplantation is 
reserved for otherwise healthy patients with end-stage congestive heart failure (CHF) 
with severely impaired function despite optimal medical therapy (Hunt, 1998). 
Nonpharmacologic measures include regular exercise for patients with stable HF 
(Pina et aI., 2003), restriction of dietary sodium intake, restriction of excess fluid intake, 
smoking cessation, restriction of dietary fat intake, abstinence from alcohol and illicit 
drugs, and treatment oflipid disorders ("ACC/AHA Guidelines," 2001; NHLBI, 2004). 
Despite these measures, the prevalence of chronic HF is increasing, and the situation of 
patients with HF will deteriorate unless new management strategies are developed 
(Cleland, 2000). 
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The effectiveness of multidisciplinary nonpharmacological approaches for 
improving outcomes for patients with HF is under evaluation (McAlister, Stewart, Ferrua, 
& McMurray, 2004). Considering the barriers to healthcare access related to funding and 
geographic location, development of remote monitoring models for delivering care must 
be considered (McAlister et aI., 2004). Remote monitoring models can include 
communication technology, such as telemonitoring (transfer of physiological data such as 
blood pressure, weight, electrocardiographic (ECG) details, and oxygen saturation 
through telephone or digital cable from home to healthcare provider) or regular structured 
telephone contacts between patients and healthcare providers, which mayor may not 
include the transfer of physiological data (McAlister et aI., 2004). 
Heart Failure and Telemonitoring Systems 
Telemonitoring permits home monitoring of patients using special telecare 
devices in conjunction with a telecommunication system. Telecare is increasingly used 
by care providers in various specialties to support chronically ill patients at home using 
existing telecommunications systems (Ahring, Ahring, Joyce, & Farid, 1992; Billard et 
aI., 1991). Telemonitoring systems can provide diagnostic information, which can be 
transmitted manually or automatically, to allow experts to evaluate patients one or more 
times per day, or even to continuously monitor them. In view of the rising costs of 
hospital care, limitation of functional capacity, and QOL in controlled settings, interest in 
telecare has grown, and rapid advances in communication and technology have facilitated 
development of patient-friendly telecare equipment (Louis et aI., 2003). 
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Telemonitoring Acceptability and Patient Satisfaction 
Six observational studies (Deering, Baines, Christianson, & Milner, 2002; de 
Lusigman et aI., 2000; de Lusigman, Meredith, Wells, Leatham, & Johnson, 1999; Knox, 
Mueller, Vuckovic, & Acker, 2002; Wang, Yu, Chau, & Lamm, 2002; Williams, Keiler, 
Sprang, & Mehan, 1998) and one randomized study (Woodend et aI., 2002) assessed 
patients' acceptance and compliance with telemonitoring (see also Louis et aI., 2003). De 
Lusigman et ai. (1999) measured acceptability and QOL scores while monitoring blood 
pressure (BP), heart rate (HR), and weight and video conferencing weekly. De Lusigman 
et al. concluded that patients using telemonitoring showed good acceptability and 
improved QOL scores after 3 months. 
De Lusigman et al. (2000) monitored heart rate, respiratory rate, ECG, and 
temperature for a 2-hour period and concluded that telemonitoring had good acceptability 
and a reliability of 95%. Deering et al. (2002) monitored weight and symptoms for an 
average follow-up of 5.3 months and concluded that telemonitoring improved patient 
satisfaction for 94% of patients. Knox et al. (2002) monitored weight, pulse rate, and 
symptoms for 8 weeks and found that telemonitoring reduced clinic visits for 
optimization of beta-blocker therapy. 
Williams et al. (1998) monitored weight and symptoms for 4 months and 
concluded that telemonitoring systems showed high compliance and patient satisfaction 
in 86% of cases. In a randomized, controlled trial comparing telemonitoring with usual 
care, Woodend et al. (2002) found high patient satisfaction and improvement in QOL 
through video conferencing with a nurse and telemonitoring of vital signs and ECG. 
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Observational Studies of Telemonitoring and Hospitalizations and Readmission Rates 
Twelve nonrandomized studies assessed the effect of telemonitoring on 
hospitalizations and readmission rates (see also Louis et al. 2003). Shah, Der, Ruggerio, 
Heidenrich, and Massie (1998) found a 50% reduction in cardiovascular admissions and 
80% acceptability after 8.5 months of patient education, automated reminders, and weight 
and blood pressure monitoring for NYHA Class II-IV patients. Cordisco, Beniaminovitz, 
Hammond, and Mancini (1999) found reduced emergency room (ER) visits and 
hospitalization rates after 12 months of telemonitoring weight and symptoms. 
Chrysegolos, Gemme, Coleman, Cheng, & Meyer (1999) monitored weight, BP, and 
ECG in NYHA Class III patients for 6 months and concluded that telemonitoring reduced 
readmission rates and ER visits. After 12-18 months, telemonitoring of weight, BP, HR, 
and O2 saturation led to a significant decrease in the number of admissions and length of 
hospital stays in NYHA Class III patients (Bondmass, Malhotra, Castro, & A vitall, 
1999). 
Heidenrich, Ruggerio, and Massie (1999) monitored weight, BP, and HR and 
provided patient education through weekly telephone calls for 7.4 months and found 
significantly reduced hospitalizations for NYHA Class II-III patients. Roglieri et al. 
(1997) used vital sign monitoring and patient education as an intervention for 3 months 
and found reduced 30- and 90-day readmission rates, length of stay, and number of 
emergency room visits. Macropoulos and Selna (2002) monitored weight and symptoms 
for 12 months and found reduced admissions rates. 
Kesinger, Gilani, and Jennison (2002) used electronic home monitoring of weight, 
symptoms, and medication compliance for NYHA Class III-IV for 7 months and found a 
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50%reduction in hospitalizations. Ertle and Litman (2002) found a 73% reduction in 
inpatient costs after 6 months of weight and symptom monitoring. Scalvini, Zanelli, 
Volterrani, and Benigno (2002) monitored symptoms and ECG for 12 months and found 
a significant reduction in hospitalizations with no difference in mortality compared to a 
control group. Lapworth and Dibiase (2000) monitored weight and symptoms ofNYHA 
Class III patients for 8 months and found a 75% reduction in hospitalizations and a 47% 
reduction in length of hospital stay. 
Randomized Studies of Telemonitoring and Hospitalizations and Mortality 
Five randomized studies assessed the effect oftelemonitoring on hospitalizations 
and mortality rates. Bondmass, Benatar, Castro, and Avitall (2001) found that 
telemonitoring weight, HR, BP, and 02 saturation resulted in fewer readmissions and 
reduced length of hospital stay for a group of telemonitored patients, compared to a group 
of patients given nurse care visits. Jerant, Azari, and Nesbitt (2001) performed two-way 
video conferencing integrated with an electronic stethoscope for 6 months with NYHA 
Class II patients and found an 86% reduction in readmission charges and an 84% 
reduction in the telemonitored group. 
Goldberg et al. (2002) telemonitored weight and symptoms ofNYHA Class 111-
IV patients for 6 months and found no difference in readmission rates compared to 
patients receiving standard care; however, there was a significant reduction in mortality 
for women under age 65. Johnson, Wheeler, Deuser, and Sousa (2000) found no 
difference in cost of healthcare after 10-12 months for patients who used video 
consultation with a nurse and patients who received standard care. Massie, West, Van 
Ostaeyen, and Salbalvaro (2001) found no significant difference in outcomes between 
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groups that did and did not receive telephonic monitoring of weight vital signs and 
symptoms. 
Technology-Driven Home Monitoring of Patients With Heart Failure 
The Health Care Financing Administration (HCF A) Heart Failure Demonstration 
Project Study Group of 2000 conducted a trial to assess the impact of a technology-driven 
HF home monitoring system on clinical and economic outcomes of Medicare 
beneficiaries who were recently hospitalized for HF. The study was conducted in 
Billings, Montana (rural); Louisville, Kentucky; and Philadelphia, Pennsylvania. Study 
subjects were randomized and received either standard HF care (as described above) or 
standard HF care supplemented by home telemonitoring. 
The purpose ofthis sub study is to (a) evaluate the effect of home telemonitoring 
systems on functional capacity (6-minute walk distance [6MWD] and 6-minute work 
[6MW]) and QOL (QOL score); (b) determine clinically meaningful difference in 
6MWD or 6MW and Minnesota Living With Heart Failure (MLHF) scores; and (c) 
determine the correlation between clinically meaningful differences in 6MWD or 6MW 
and QOL (MLHF score) in patients with chronic HF. 
Rationale for the Study 
Congestive heart failure (CHF) is a major health problem with increasing 
incidence and a poor prognosis. It is often accompanied by multiple comorbidities, 
disability, depression, and cognitive impairment and leads to deterioration in functional 
capacity and QOL (Stott, 2002; Wielenga et aI., 1997). Efforts must be made to develop 
novel strategies to reduce the rising cost of care for patients with HF without 
compromising the standard of care. 
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Louis et al. (2003) conducted a systematic review of telemonitoring studies and 
concluded that telemonitoring might have an important role as part of a strategy for 
delivery of healthcare for patients with HF. Several multidisciplinary programs and 
remote monitoring models were evaluated for effectiveness in terms of a statistically 
significant difference in outcomes, but none of the studies made definitive conclusions 
about the clinical significance of such strategies for improving outcomes like functional 
capacity and QOL (Louis et al., 2003). Thus, integration of technology-driven HF 
monitoring into standard care and assessing its impact in terms of clinically significant 
improvement in QOL and functional capacity is imperative to designing sound 
multidisciplinary disease management models. 
Because of the complexity and cost associated with implementing many disease 
management programs for patients with HF, there is a need for a simpler, less personnel-
intensive, more cost-effective approach to the longitudinal care of these patients. Despite 
the high prevalence of HF, there have been very few studies of the impact of CHF on 
functional capacity and QOL, suggesting the need for epidemiological studies on 
functional capacity and QOL (Davis et al., 1999). 
In the context of preventive and therapeutic cardiology, functional capacity and 
QOL are important outcome measures for evaluating the effectiveness oftreatment 
strategies and the course of a disease (Bullinger, 1997; Wenger, 1989). Therefore, 
functional capacity and QOL are major goals in the context of preventive and therapeutic 
cardiology. It is, therefore, imperative to test the impact of technology-driven therapeutic 
modalities ofHF management on functional capacity and QOL of patients with CHF. 
With increased rates of patient adherence, compliance, and acceptance of telemonitoring 
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technology to monitor HF symptoms (Capomolla, Pinna, La Rovere, Maestri, & Ceresa, 
2004; de Lusigman et al., 1999,2000), various investigators are in the process of 
developing and evaluating several telemonitoring systems. For example, the HCF A 
Demonstration Project Study Group investigated the effectiveness of a technology-driven 
home te1emonitoring system for Medicare beneficiaries with chronic HF. 
Significance of the Study 
The purpose of this study is to evaluate the effect of a technology-driven home 
telemonitoring system on functional capacity using 6MWD or 6MW and on QOL using 
MLHF. Small differences in functional capacity and QOL may be statistically significant 
but clinically unimportant. Therefore, it is necessary to determine the smallest difference 
considered worthwhile or clinically important (Hays & Woolley, 2000). The purpose of 
this study is to determine clinically meaningful differences in the 6MWD or 6MW and 
MLHF scores of patients with chronic HF. 
The MLHF scale is superior and more responsive to changes in QOL compared to 
the Chronic Heart Failure Questionnaire (CHQ) and the General Health Survey Short 
Form 12 and 36 (SF-12 and SF-36) instruments (Bennet et al., 2002; Ni, Toy, Burgess, & 
Wise, 2000). Therefore, the purpose of this study is to determine changes in MLHF 
scores that are indicative of clinically meaningful change in the QOL of patients with HF. 
In a randomized control study, Guyatt, Townsend, Keller, Singer, and Nogradi 
(1991) concluded that 6MWD better correlated with formal measures of QOL for patients 
with chronic lung disease. Carter et al. (2003) stated that 6-minute distance times 
bodyweight product (6MW expressed in kilograms per meter) was an improved outcome 
measure to estimate the functional capacity of COPD patients. The purpose of this study 
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is to determine the relationship between clinically meaningful change in 6MWD or 6MW 




CHF is a major health problem with increasing incidence and a poor prognosis. It 
is often accompanied by multiple comorbidities, disability, depression, and cognitive 
impairment and leads to deterioration in functional capacity and QOL (Stott, 2002; 
Wielenga et aI., 1997). Therefore, functional capacity and QOL should be included as 
important outcome measures when developing disease management models for patients 
with HF. Davis et aI. (1999) stated that there was a lack of data on the effect of disease 
monitoring systems on functional capacity and QOL for patients with HF. 
Functional Capacity 
Functional capacity refers to the performance of, or the capacity to perform, 
regular daily activities (Leidy, 1994). Such activities require the integrated efforts of the 
heart, lungs, and circulation to deliver oxygen to the metabolically active muscle mass to 
perform work (Gibbons et aI., 1997). The capacity of an individual to perform work is 
defined by the maximal oxygen consumption (V02 max), the product of cardiac output 
(CO), and arteriovenous oxygen (A V02) difference at exhaustion (Rowell, 1988). 
Functional capacity is often expressed in metabolic equivalents (METs); 1 MET 
represents resting energy expenditure, which is approximately 3.5 mL O2 . kg-
l 
. min- l 
(Fleg & Lakatta, 1988; Rowell, 1988). Functional capacity is affected by age, sex, the 
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presence of disease, and medications that affect aerobic exercise (Fleg & Lakatta, 1988; 
Pollock et aI., 1998). 
Measuring Functional Capacity 
In the hospital setting, functional capacity can be directly measured by 
determining V02 max or can be estimated using the highest treadmill or stationary cycle 
ergo meter work rate achieved (Jerome et al., 2000). Peak oxygen uptake (peak V02) is a 
reference parameter, or gold standard, in the assessment of functional capacity of patients 
with HF; however, the procedure for measuring peak oxygen uptake is complex, 
invasive, and expensive. Outside the hospital setting, the most widely used methods for 
assessing functional capacity, the 6MWT and shuttle walk test, are simple, noninvasive, 
and inexpensive. For the 6MWT, patients are instructed to walk as far as they can in 6 
minutes. In the shuttle walk test, patients are pressured to meet multiple deadlines 
through audio cassette beeps. The 6MWT is self-paced and less likely than the shuttle 
walk test to push patients beyond their endurance or through angina or other pain (Paul, 
2003). 
6-Minute Walk Test 
The 6MWT is a practical, simple test that requires a 100-foot hallway but no 
exercise equipment or advanced technician training. The test measures the distance that a 
patient can quickly walk on a flat, hard surface in a period of 6 minutes, known as the 
6MWD. Functional capacity, or exercise capacity, is determined by the integrated 
response of multiple systems, including the pulmonary, cardiovascular, hematopoietic, 
neuromuscular, and metabolic (A TS, 2002). The 6MWT does not provide specific 
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information on the function of each organ and system involved in the exercise 
mechanism; instead, it serves as a surrogate estimate of the collective mechanism. 
Most activities of daily living are performed at a sub maximal level. The self-
paced 6MWT assesses the sub maximal level of functional capacity. Often, patients do 
not achieve maximum exercise capacity during the 6MWT; instead, they choose their 
own intensity of exercise and are allowed to stop and rest during the test (A TS, 2002). 
The test has been shown to be useful in assessing prognosis and exercise capacity in 
several studies (Bittner et aI., 1993; Cahlin, Mathier, Semigran, Dec, & Disavo, 1996; 
Guyatt, Thompson, et al., 1985; Roul, Germain, & Bareiss, 1998; Zugck et al., 1998). In 
clinical practice, the 6MWT is used for measuring the response to medical interventions 
for patients with moderate to severe heart or lung disease (ATS, 2002). 
There is a moderate correlation between distance walked during the 6MWT and 
peak V02 (L = 0.70), P < .001) and close correlation between distance walked during the 
shuttle walk test and peak V02 (L= 0.83, P < .001; Morales et aI., 1999). Solway et aI. 
(2001) performed a qualitative review of measurement properties of the shuttle walk test 
and 6MWT and concluded that exercise performed during the shuttle walk test was 
similar to a symptom-limited, maximal, incremental treadmill test. The shuttle walk test 
is more difficult to administer, requires more equipment, and is less reflective of activities 
of daily living (ATS, 2002; Solway et al., 2001). The 6MWT is easy to administer, better 
tolerated, and more reflective of activities of daily living. Therefore, currently, the 
6MWT is the test of choice when administering a functional walk test for clinical or 
research purposes (ATS, 2002; Solway et aI., 2001). 
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As a test of submaximum exercise capacity with high validity and minimal 
potential for cardiovascular problems (Demers et ai., 2001), the 6MWT mimics daily 
activity (Solway et ai., 2001) and is more relevant to both doctor and patient than the 
maximum exercise test (ATS, 2002). Demers et al. (2001) investigated the reliability, 
validity, and responsiveness of the 6MWT for patients with HF and concluded that the 
6MWT was highly reproducible (intraclass correlation coefficient [ICC] = 0.90), 
moderately and inversely correlated to NYHA functional class (L = -0.43,:Q = 0.001), and 
weakly inversely correlated to cumulative QOL (MLHF score; L = -0.26,:Q = 0.0001). 
In an observational study, O'Keffe, Lye, Donnellan, and Carmichael (1998) 
concluded that the 6MWD was more responsive to deterioration than improvement of HF 
symptoms. There are several factors that influence the 6MWT: a shorter 6MWD may be 
associated with shorter height (short legs), older age, greater body weight, female gender, 
impaired cognition, shorter walking corridor (more turns), acute or chronic lung diseases, 
cardiovascular diseases, chronic degenerative diseases, and musculoskeletal injuries or 
deformities (Paul, 2003). Factors associated with a longer 6MWD are taller height 
(longer legs), male gender, high motivation, and medications increasing aerobic exercise. 
The effect of these factors must be considered when drawing conclusions about 
functional capacity. The strongest indication of the 6MWT is for measuring the response 
to medical interventions of patients with moderate to severe heart or lung disease (AT A, 
2002). The 6MWT has also been used as a measure of functional status of patients as 
well as a predictor of morbidity and mortality (ATS, 2002). 
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6-Minute Work 
Distance covered during the 6MWT doesn't take into account differences in 
bodyweight that are known to influence exercise capacity. Chuang, Lin, and Wasserman 
(2001) investigated the calculation of the product of bodyweight and walking distance as 
an alternative method for assessing functional capacity. This calculation accounts for 
bodyweight differences, and estimates work and energy expenditure through the formula 
Force x Distance (Chuang et aI., 2001). Carter et ai. (2003) stated that 6MWD (in 
meters) x bodyweight (in kilograms), or 6MW expressed in kilograms per meter of work, 
was an improved outcome measure to estimate functional capacity for COPD patients. 
For COPD patients, 6MW yielded higher correlation coefficients than 6MWD 
when correlated with pulmonary function indices, including lung diffusion for alveolar 
ventilation, DLco (L = 0.6 vs. 0.46,.Q... = 0.0001), forced expiratory volume in one minute 
(L = 0.52 vs. 0.38,12 = 0.0001), forced vital capacity (L = 0.48 vs. 0.38,12 = 0.0001), vital 
capacity (L = 0.48 vs. 0.40,12 = 0.0001), and cycle ergometry gas exchange indices, 
including work (in watts; L = 0.79 vs. 0.59,12 = 0.0001), peak oxygen uptake (L = 0.81 vs. 
0.54,12= 0.0001), peak minute ventilation (0.59 vs. 0.46,12 = 0.0001), and peak tidal 
volume (L = 0.57 vs. 0.43,12 = 0.0001). The ROC curve demonstrated that 6MW had a 
significantly larger calculated area under the curve (0.782 vs. 0.708,12 < 0.05) than 
6MWD (Carter et aI., 2003). 
The pathophysiology ofHF is entirely different from that of CO PD. Functional 
capacity of patients with HF is determined by degree of debilitation from frequent 
decompensation. Fluctuations in weight may be very rapid and unpredictable. However, 
the applicability and correlation of 6MW to HF indices has not been evaluated. Even if a 
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statistically significant difference exists between correlation coefficients and the area 
under the curves of 6MWD and 6MW, the clinical significance of those differences has 
not been determined. 
Quality of Life 
Definition 
The World Health Organization (WHO, 1946) defined health as "a state of 
complete physical, mental, and social well-being and not merely the absence of disease or 
infirmity". Health status is typically used to represent the patient's subjective (or 
perceived) appraisal of his or her state of physical and mental health (Revicki et al., 
2000). The concept of QOL lacks clarity and uniform definition. Health status, 
functional status, and QOL are three concepts often used interchangeably when referring 
to health. 
Gill and Feinstein (1994) stated that QOL incorporates patient values, judgments, 
and preferences and that these are subjective experiences, states, and perceptions of one's 
overall well-being, including aspects of the physical, psychological, social, economic, 
and political environment (Revicki et al., 2000). Guyatt (1993) used the term health-
related QOL (HRQOL) because many widely valued aspects of life, such as income, 
freedom, and quality of the environment, are not generally considered health-related. 
Testa and Simonson (1996) defined HRQOL as the "physical, psychological and 
social domains of health, seen as distinct areas that are influenced by a person's 
experiences, beliefs, expectations and perceptions" (p. 835). QOL is a broad term that 
comprises subjective domains as assessed by patients-physical functioning, 
psychological functioning, and social functioning-and objective domains as assessed by 
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healthcare and social support personnel and measured by laboratory or diagnostic tests-
psychophatology (CID-IO/DSM-IV-TR), socioeconomic status, and social support (Rui 
et al., 2005). Therefore, the goals of disease management for patients with chronic HF 
should be directed at improving symptoms, stabilization or improvement in functional 
abilities, and improved comfort for the duration of life (Wenger, 1989). 
F or asymptomatic patients with HF, the management strategies should aim to 
improve ventricular function in order to improve long-term survival and eliminate 
interference with QOL, which will improve compliance and enhance long-term outcome 
advantages (Wenger, 1989). Majania et al. (1999) found that subjective domains were 
highly correlated with a global sense of well-being, and objective domains were less 
correlated with a global sense of well-being. QOL reflects subjective perceptions of 
harmony within the body and between a patient and the external world (Katsching, 1997). 
Measures of Quality of Life 
Measures of QOL fall into two categories: (a) generic measures, which attempt to 
provide a summary of a patient's perceived QOL, and (b) disease-specific measures, 
which focus on problems associated with particular disease states and patient groups 
(Guyatt, 1993). Generic measures can be standardized and applied to a wide variety of 
illnesses to allow for comparisons (Dempster & Donnelly, 2000). Early QOL research 
used psychological well-being scales, including the Affect Balance Scale by Bradburn 
(1969), the Quality of Well-Being Scale by Kaplan and Anderson (1988), and the 
Psychological General Well-Being Index by Dupuy (1984). Later research included the 
Sickness Impact Profile by Gilson et al. (1975); the Nottingham Health Profile by Hunt et 
al. (1980) and the Rand SF-36 Health Status Profile by Ware et al. (1993). 
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Generic measures lack the range, sensitivity, and flexibility to deal with a 
particular illness (Dempster et aI., 2000). Therefore, disease-specific QOL instruments 
were developed. Disease-specific instruments are more responsive and more sensitive to 
changes (Spertus, Winder, Dewhurst, Deyo, & Stephan, 1994). Some examples of 
disease-specific instruments to measure QOL in patients with HF are the Chronic Heart 
Failure Questionnaire (Guyatt et aI., 1989), the Minnesota Living with Heart Failure 
Questionnaire (Rector, Kubo, & Cohn, 1992), and the Kansas City Cardiomyopathy 
Questionnaire (Green, Porter, Bresnahan, & Spertus, 2000). 
Although numerous instruments are available to measure QOL, the most 
commonly used instruments in HF research are generic instruments (SF-12 and SF-36) 
and disease-specific instruments (CHQ and MLHF). Bennett et ai. (2002) conducted a 
study to compare the psychometric properties of these instruments and concluded that all 
instruments were reliable and valid; however, CHQ and MLHF were more sensitive and 
responsive to changing conditions than generic measures were. Considering the 
feasibility of administering these instruments and their responsiveness to changes in 
QOL, MLHF is superior to CHQ, SF-12, and SF-36 (Bennet et aI., 2002; Ni et aI., 2000). 
Minnesota Living With Heart Failure Questionnaire 
The MLHF questionnaire is a disease-specific instrument designed to measure the 
effects ofHF and treatments for HF on QOL (Rector et aI., 1992). It is composed of21 
items and three subscales measuring the following dimensions: (a) the physical 
functioning dimension (eight items), (b) the emotional functioning dimension (five 
items), and (c) an overall QOL score (all 21 items). Eight separate items not assessing an 
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underlying construct or dimension ofHQOL measure social and economic impairment 
for patients due to HF and are part of the overall score. 
To measure the effects of symptoms, functional limitations, and psychological 
distress on an individual's QOL, the MLHF questionnaire asks each person to indicate 
using a 6-point Likert scale (0 to 5) to what extent each of the 21 facets prevent them 
from living as they desire. The questionnaire results in a total score between 0 (no 
impairment) and 105 (severe impairment), which represents the physical, socioeconomic, 
and psychological impairments of HF that affect QOL. 
Factor analysis identifies two components on the questionnaire-physical and 
emotional. The associations between patients' overall ratings of how much HF prevented 
them from living as they wanted (r... = 0.8, 2 < 0.01) and their NYHA classification (r... = 
0.60,2< 0.01) suggest that the MLHF score is a valid representation of patient 
impairment (Rector et aI., 1992). The test-retest reliability of the MLHF score was r... = 
0.93 (2 < 0.001) for the total score, r... = 0.89 ill < 0.001) for the physical dimension 
subscore, and r... = 0.88 ill < 0.001) for the emotional dimension subscore (Rector & Cohn, 
1992). 
Clinically Meaningful Difference 
Definition 
Jaeschke, Singer, and Guyatt (1989) defined minimal important difference as 
the smallest difference in score in the domain of interest which patients perceive 
as beneficial and which would mandate, in the absence of troublesome side-
effects and excessive cost, a change in the patient's management. (p. 407) 
Small numerical differences in mean scores might give statistically significant 
results when large sample sizes are used, but statistical significance is not equivalent to 
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clinical significance (Osoba et aI., 1998). Currently, there are no guidelines or standards 
to help physicians determine whether or not the treatment provided to patients with CHF 
results in a clinically meaningful change in their functional capacity and QOL. The 
purpose of this study is to define the level of change in functional capacity (measured by 
6MWD or 6MW) and QOL (measured by MLHF) that is clinically meaningful for 
patients with CHF. 
Measuring Clinically Meaningful Difference 
There are two approaches for determining meaningful change: (a) the distribution 
based-approach and (b) the anchor-based approach. 
Distribution-Based Approach 
Distribution-based approaches to determining clinically meaningful change are 
based on the statistical characteristics of the obtained sample. To estimate the effect size 
(Cohen, 1988; Kazis et aI., 1989) or standard error of measurement (SEM; McHorney & 
Tarlov, 1995; Wyrwich, Tierney, & Wolinsky 1999), distribution-based methods use the 
empirical distribution of a measure and its psychometric characteristics. Therefore, 
distribution-based methods rely only on statistical and psychometric properties of a 
measure. 
Distribution-based measures fall under three broad categories. First, measures 
based on statistical significance evaluate change in relation to the probability that change 
occurred by random variation. Examples are paired !-statistic (Husted et aI., 2000) and 
growth curve analyses (Speer & Greenbaum, 1995). Second, measures based on sample 
variation evaluate change in relation to sample variation. Some examples are effect size 
(Cohen, 1988; Kazis, Anderson, & Meenan, 1989), standardized response mean (Stucki 
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et aI., 1995), and responsiveness statistic (Guyatt, Bombardier, & Tugwell, 1986). The 
final category of measures includes those based on the measurement precision of the 
instrument. Some examples are SEM (Wywich et al. 1999) and reliable change index 
(Jacobson & Truax, 1991). 
According to Crosby, Kolotkin, and Williams (2003), 
the most promising distribution-based measures for establishing clinically 
meaningful change are those based on the measurement precision of the 
instrument (Standard Error of Measurement, SEM and Reliable Change Index, 
RCI). Because these measures quantify the amount of error inherent in the 
instrument and the amount of random variation that can be expected in repeated 
administrations. In addition, they are not influenced to a large degree by 
variability in the sample at baseline (as is the effect size), variability of the 
observed change (as are the Standardized Response Mean, SRM and the 
Responsiveness Statistic), or the sample size (as are the !-statistic and growth 
curve analysis). These precision measures can be used to establish cutoffs based 
on a desired confidence level. (p. 400) 
Anchor-Based Approach 
Anchor-based methods define a clinical standard for comparison using the 
patient's or physician's perception of change as an external anchor to estimate the clinical 
meaningfulness of corresponding change (Jaeschke et al., 1989). Anchor-based 
approaches have been used to determine clinically meaningful change via cross-sectional 
and longitudinal methods. Various cross-sectional methods described in the literature 
include comparison to disease-related criteria (Deyo et al., 1992; Johnson, Goldman, & 
Orav, 1995), comparison to non-disease-related criteria (Testa & Lenderking, 1992; Testa 
& Simonson, 1996), preference ratings (Llewellyn-Thomas, 1996) and comparison to 
known populations (Jacobson & Truax, 1991). 
One of the limitations of cross-sectional comparisons is that groups are likely to 
differ in many relevant variables besides HRQOL. Samsa et al. (1999) suggested 
statistically controlling these variables using regression methods and calculating effect 
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sizes based on adjusted mean differences. The most commonly used anchor-based 
approaches for establishing clinically meaningful change in longitudinal studies focus on 
global ratings of change (Jaeschke et aI., 1989; Stucki et aI., 1995), prediction of 
prognosis of future events (Mossey & Shapiro, 1982), and changes in disease-related 
outcomes (Kolotkin, Crosby, & Williams, 2002). 
According to Crosby et al. (2003), 
Longitudinal anchor-based methods are more directly linked with change when 
compared to cross-sectional methods because the former are more directly linked 
with change. Hence longitudinal anchor-based methods are preferable to cross-
sectional methods. In considering these longitudinal methods, patient global 
ratings are especially well suited for assessing patient's perception of change and 
are recommended for that purpose. However, when using global ratings, it is 
important to assess the reliability of these ratings. Clinician global ratings and 
longitudinal disease-related measures of outcome are the most suitable methods of 
determining meaningful change from the clinical perspective. (p. 399) 
Integration of Distribution- and Anchor-Based Methods 
It's not clear whether it is better to use anchor-based or distribution-based 
methods for determining clinically meaningful change. There have been some attempts 
to integrate anchor- and distribution-based approaches. Jacobson and Truax (1991) 
proposed that individuals should be considered improved or deteriorated only when they 
meet both the anchor- and distribution-based criteria for change. Another study by Cella 
et al. (2002) to determine clinically meaningful change on the Functional Assessment of 
Cancer Therapy-Lung (FACT -L) questionnaire described that clinically meaningful 
change determined by anchor-based methods (e.g., differences between clinically 
distinguishable groups) was confirmed by distribution-based methods (e.g., effect size, 
SEM). The agreement across these methods was high, with kappa ranging from 0.71 to 
1.0. Individuals with the greatest impairments at baseline have the greatest opportunity 
for improvement compared to individuals with less extreme scores. 
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Failure to take RTM (RTM) into account may lead to erroneously concluding that 
those with severe impairments have shown clinically meaningful improvement, when 
much of that change is due to R TM (Barnett, VanDer Pol, & Dobson, 2005). Cella et al. 
(2002), Guyatt and Jaeschke (1997), Hays and Woolley (2000), Juniper, Guyatt, Willan, 
and Griffith (1994), and Ware et al. (1993) reported that when a patient is improving, a 
smaller amount of change may be considered clinically important than when the patient 
worsening. Therefore, direction of change should be accounted for when defining 
clinically meaningful change. 
Kolotkin et al. (2002) described a method to determine clinically meaningful 
change in obesity-specific QOL using the combined information from anchor-based 
(weight loss) and distribution-based (SEM corrected for RTM) methods, taking into 
account baseline impairment and direction of change. Speer (1992) mentioned that while 
defining clinically meaningful difference, if regression to the mean is not present, then 
the Jacobson and Truax (1991) method is more appropriate. 
Jacobson and Truax (1991) proposed a two-step method. The first step is to 
define cutoff points that separate a functional population from a dysfunctional population. 
For example, Cutoff A specifies the functional population as those with post-therapy 
scores that are two standard deviations (SDs) or more from the pretreatment mean. The 
second step compares individual's change from pre- to post-therapy to the standard error 
(SE) of measurement of the outcome (± 1.96 SE), referred to as reliable change index 
(RCI). 
These two steps classify individuals into four categories: recovered (individual 
has passed Cutoff A and RCI in the positive direction), improved (passed RCI in the 
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positive direction but not Cutoff A), unchanged (passed neither criterion), or deteriorated 
(passed RCI in the negative direction). IfRTM is present, the Edwards-NUlU1ally (EN) 
method is more appropriate than the Jacobson and Truax method (Edwards et aI., 1978). 
The EN method addresses regression to the mean by shrinking pretherapy scores toward 
the pretherapy mean using the reliability of the measure. The estimated true score is then 
placed at the center of a confidence interval so that estimates can be made of the 
significance of post-therapy change, or two SEs from the adjusted center. 
Crosby, Kolotkin, and Williams (2004) designed an integrated method that 
combined information from anchor- and distribution-based methods using data 
aggregated from weight-loss studies. A total of 1,476 weight-loss study participants were 
evaluated at baseline and at 6 months using the Impact of Weight on Quality of Life-Lite 
(IWQOL-Lite). Then, Crosby et al. used the EN method and corrected SEM for 
regression to the mean. 
Clinically Meaningful Change in 6-Minute Walk Distance 
Using distribution-based methods, G. Claire, Martin, Joseph, Tamiza, and 
Stephen (2005) conducted a study of pulmonary hypertension patients to explore 
minimally important difference (MID) for 6MWD and SF-36 domains. They concluded 
the MID for 6MWD was 39 m, and for SF-36, the MID for physical functioning was 11 
m; role physical, 21; social functioning, 16; and vitality, 13. 
Redelmier, Bayoumi, Goldstein, and Guyatt (1997) conducted a study of patients 
with chronic lung disease and found that the 6MW was significantly correlated with 
patients' ratings of their walking ability relative to other patients (L = 0.59,95% 
confidence interval [CI]: 0.54 to 0.63). Distances must differ by 54 m for the average 
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patient to stop rating themselves as about the same and start rating themselves as either f! 
little bit better or a little bit worse (95% CI: 37 to 71 m). 
Cooper (2001) conducted a study of patients with chronic pulmonary disease and 
considered a 54-meter change in 6MWD to be clinically meaningful based on the 
conclusions of Redelmier et al. (1997). Perera, Mody, Woodman, and Studenski (2006) 
conducted a secondary analysis of data from an observational study and clinical trials of 
community-dwelling older adults and subacute stroke survivors. Perera et al. calculated 
the effect size using distribution-based methods (Cohen, 1988; Kazis et aI., 1989; Testa, 
1987) and concluded that small meaningful change in 6MWD was 20 m and substantial 
change was 50 m. In these trials, RTM and reliability of the instrument were not taken 
into account when defining meaningful change in 6MWD. 
Clinically Meaningful Change in MLHF Score 
According to Rector (2005), clinically meaningful refers to an effect that would 
prompt patients and physicians to consider using a treatment if the risk and costs were 
acceptable. So far, there has been no gold standard to determine cutoff values for 
changes in QOL in terms of improvement or deterioration. Rector et aI. (1995) found 
that an improvement of 5 points in the MLHF score was sufficient to be clinically 
effective for a majority of patients to take a medication that had no side effects or costs. 
According to Bennet et al. (2002), a change of 5 points was the minimum clinically 
meaningful change based on the mean change in the MLHF score observed in a group of 
patients who rated their change in overall condition as ± 2 or ± 3 on a -7 to +7 scale. 
Cohen (1988) provided benchmarks to serve as a guide for interpreting effect size, 
where effect size = (mean at baseline - mean at follow-up )/standard deviation at baseline. 
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For small effects, the benchmark was 0.2; for moderate effects, 0.5; and for large effects, 
0.8. Based on a comprehensive review of the literature, an effect size of 0.2 should serve 
as an appropriate definition of the minimum clinically important difference (Samsa et aI., 
1999). Using effect size calculations, conclusions of clinically meaningful change at the 
individual level may be influenced by the heterogeneity of the sample. In addition, the 
effect size doesn't take into account the variability of change, the test-retest reliability of 
the instrument, and R TM. 
Wyrwich, Nienaber, et al. (1999) suggested that a change of 1 SEM was clinically 
meaningful. The I-SEM (baseline) threshold is equivalent to 0.71 SEM change, and 
approximately 52% of the area under the normal curve is between Z = -0.71 and Z = 0.71 
(Wyrwich, Nienaber, et al. 1999). To decide if an improvement or deterioration has 
occurred at the individual level, a 51 % level of certainty may be applied (Donaldson & 
Moinpour,2002). A higher level of certainty (90%-95%) is needed to compare 
statistically significant differences at the group level but not at the individual level. 
Therefore, at the individual level, change over time exceeding these limits of the ± SEM 
baseline are likely to reflect a minimum important change rather than merely 
demonstrating measurement error or trivial fluctuations of chronic disease measures 
(Wyrwich, Nienaber, et aI., 1999). 
SEM is an estimate of error for use in interpreting individual test scores. A test 
score is an estimate of a person's true test performance. Using a reliability coefficient 
and the test's SD, this value may be calculated as follows: 
SEM = SD*[" (1 - r)] 
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(1) 
Where SD = the standard deviation for the test, and r = the reliability coefficient 
for the test. 
The higher a test's reliability coefficient, the smaller the test's SEM is. The larger 
the SEM, the less reliable the test is. There are no studies that define clinically 






F or patients previously hospitalized with HF and with continued symptoms of HF, 
addition of technology-driven HF management to standard care may be associated with 
clinically meaningful effects when compared to standard medical care alone. 
Primary Hypothesis 1 
Research hypothesis: Technology-driven HF management is associated with 
clinically meaningful effect on functional capacity measured in terms of 6MWD or 6MW 
after 6-months follow-up in elderly patients with HF 
Null hypothesis: Technology-driven HF management is not associated with 
clinically meaningful effect on functional capacity measured in terms of 6MWD or 6MW 
after 6-months follow-up in elderly patients with HF. 
Primary Hypothesis 2 
Research hypothesis: Technology-driven HF management is associated with 
clinically meaningful effect on QOL measured in terms ofMLHF score after 6-month 
follow-up in elderly patients with HF 
Null hypothesis: Technology-driven HF management is not associated with 
clinically meaningful effect on QOL measured in terms of MLHF score after 6-month 
follow-up in elderly patients with HF. 
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Secondary Hypothesis 1 
Research hypothesis: There is a correlation between clinically meaningful change 
in functional and the QOL in elderly patients with HF after 6-months follow-up. 
Null hypothesis: There was no correlation between clinically meaningful change 
in functional capacity and the QOL in elderly patients with HF after 6-months follow-up. 
Secondary Hypothesis 2 
Research hypothesis: Clinically meaningful change in QOL is responsive to 
clinically meaningful change in functional capacity after 6-months follow-up in elderly 
patients with HF. 
Null hypothesis: Clinically meaningful change in QOL is not responsive to 
clinically meaningful change in functional capacity after 6-months follow-up in elderly 
patients with HF. 
Study Design 
The HCF A Demonstration Project Study Group designed a randomized trial for 
adding a home telemonitoring system to the standard of care for Medicare beneficiaries 
with a primary diagnosis of chronic HF and with continued HF symptoms and who were 
discharged from an acute care hospital within the previous 6 months. The study was 
designed to assess the incremental effect of adding a home telemonitoring system to 
standard care on health outcomes, resource utilization, and costs and processes of care for 
patients with HF. 
Subjects were enrolled and randomized between January 2001 and January 2003. 
To examine whether the initial effectiveness oftelemonitoring system would persist or 
decay over time, a novel method of randomization was implemented. Six months after 
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initial randomization and follow-up, subjects who had been randomly assigned to follow 
a home monitoring system were1erandomized to either continue with the home 
telemonitoring system or standard care alone. Both groups were followed for an 
additional 6 months. 
The end points of the HCF A study included cardiovascular rehospitalization or 
cardiovascular death within 6 months following study randomization. The secondary end 
points explored potential continued benefit and attenuation of benefit over 12 months 
after randomization. Using the HF demonstration project data from the HCF A 
Demonstration Project Study Group, the effect of adding technology-driven HF 
management to standard care on functional capacity (assessed using 6MWD or 6MW) 
and QOL (assessed using MLHF score) for patients with chronic HF was assessed in this 
sub-study. The purpose of this study was to determine the clinically meaningful change 
in 6MWD or 6MW and QOL (MLHF scores) and to explore the correlation among these 
variables (if any). 
Study Setting 
Participants for the main study were recruited from the followings sites: St. 
Vincent's Hospital and Health Center in Billings, Montana; Jewish Hospital University of 
Louisville School of Medicine in Louisville, Kentucky; and University of Pennsylvania 
Health System, Philadelphia, Pennsylvania. 
Eligibility Criteria 
Participants must be Medicare beneficiaries aged 65 years or older who were 
discharged from an acute care hospital with a primary diagnosis ofHF (DRG 127) within 
the preceding 6 months. The following criteria also had to be met: (a) evidence ofHF 
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(left ventricular ejection fraction < 50% documented on echocardiography, radionuclide 
ventriculography, or cardiac catheterization) and currently experiencing symptoms of HF; 
(b) ability to stand for 20 s without holding the wall; (c) bodyweight less than 400 
pounds; (d) ability to speak English or Spanish (required for the use of the home 
telemonitoring system); (e) ability to complete a 6MWT; (f) ability to provide witnessed, 
written informed consent for all aspects of the study, including permission to provide or 
access the clinical, health status, and medical service utilization data required by the 
study protocol prior to enrollment and randomization. 
The following subjects were excluded from the study: (a) those participating in 
other ongoing HF research or demonstration studies or having prior experience with the 
Alere DayLink Monitoring System; (b) those lacking a phone line or accessible phone 
jack in the home, as required by the home telemonitoring system; (c) Medicare managed 
care participants; (d) patients with chronic dialysis, a serum creatinine level over 3.0 in 
the past 30 days, and anticipated initiation of dialysis within 6 months; (e) patients who 
had a heart transplant; (f) patients with uncorrected thyroid disease; and (g) patients with 
end-stage or terminal illness such as metastatic malignancy or AIDS with anticipated life 
expectancy less than 6 months in addition to HF, or a score less than or equal to 25 on a 
minimental status exam. 
Subject Identification and Enrollment 
At each study site, clinical research coordinators (CRCs) identified physicians 
who were interested in recruiting patients for the study. After obtaining patients' 
permission, CRCs reviewed current and past admission records. All personnel had 
HIP AA training and strictly adhered to HIPAA procedures. Patients hospitalized with a 
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primary diagnosis of HF who were Medicare beneficiaries aged 65 or older were 
identified. After reviewing their hospital records, CRCs identified potentially eligible 
discharged patients who had been recently hospitalized. After screening eligible patients, 
CRCs contacted attending physicians to confirm eligibility and obtain the attending 
physician's consent to recruit the potential participants. 
After confirming eligibility and obtaining the attending physician's consent, 
CRCs contacted potential participants by phone and explained the study. Patients who 
expressed interest were scheduled for a baseline visit within 2 weeks to obtain written, 
signed, dated, and witnessed informed consent, at which time the data coordination center 
(DCC) was contacted to begin the randomization process and baseline data collection. 
Upon enrollment, the following procedures were performed. 
1. Study coordinators obtained the results of MUGA, ECHO, or angiography, if 
performed, from the past year. If such a test had not been performed, the 
study coordinator requested the physician prescribe one to be completed 
within 6 weeks of enrollment, especially to assess ejection fraction. 
2. Study coordinators obtained demographic data, medical history, medications, 
physician assessment data at baseline (screening visit), and baseline 
laboratory data including serum sodium, creatinine, blood urea nitrogen 
(BUN), total bilirubin, potassium, digoxin trough level, and ECG results. If 
laboratory data were not available, they were obtained within 2 weeks of 
baseline visit. 
3. Patients completed a baseline 6MWT, and study coordinators documented the 
results. 
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4. Patients completed QOL questionnaires with the assistance ofthe 
coordinators. 
5. Study coordinators provided participants with HF diaries and educational 
material, explained the importance of self-monitoring and daily recording of 
weight in the HF dairy, emphasized the importance of bringing the diary to 
each physician visit, and scheduled a 6-month follow-up visit. 
Randomization 
Eligible subjects who provided written informed consent were randomized using a 
1: 1 ratio to the control group (standard HF care) or the intervention group (standard HF 
care plus home telemonitoring). Randomization was performed at each site to control 
practice-site-specific bias or confounding effects. Randomization was performed prior to 
collection of baseline data as soon as eligibility was confirmed to avoid selection bias. 
Each enrolled participant was assigned a unique randomization number and unique study 
number. These numbers were maintained in a central log at the DCC. All enrollment 
and randomization logs were maintained by local CRCs. 
Intervention 
The HCF A HF Demonstration Project Study Group replicated as much standard 
medical care as possible among participants. Therefore, standard HF care was provided 
as background therapy for participants in both groups. The only difference between the 
two study groups was the addition of a technology-driven HF home telemonitoring 
system to the standard of care for the intervention group. 
The Alere DayLink Monitoring System was chosen for this study because Alere 
was the first company to offer in-home telemonitoring and the system was used in the 
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Weight Monitoring in Heart Failure (WHARF) trial (Goldberg et aI., 2002). Upon 
completion of the randomization process, the study coordinator faxed patient 
demographics, history, and medications at the time of enrollment to Alere Medical Inc. 
At the time ofthe study, Alere was licensed to do business in California and had its 
corporate headquarters in San Francisco with satellite centers in 25 U.S. states. It 
supported more than 30,000 patients, and its call center was staffed with trained 
personnel 7 days a week, 365 days a year, from 7:00 a.m. to 5:00 p.m. Pacific Standard 
Time. 
After receiving patients' information, Alere shipped the devices on the same day 
so that patients would receive them the next day at their homes. Installation of the device 
was simple, and instructions were mailed to participants along with the devices. By 
following instructions, participants connected the three color-coded cables to the required 
jacks. After the unit was connected to a power source, the set-up was completed 
automatically. The black box (console) prompted participants throughout the installation 
process by instructing them to press yes or no keys on the console. By following the 
prompts, the patient or family member could complete the set-up. After completing the 
set-up, the device was ready to use. 
Per protocol, twice daily, the console visibly and audibly prompted participants to 
step onto a scale for weighing. After recording their weight, the console compared 
patients' weight to the preset weight, or dry weight. Then the console prompted 
participants to answer several preset questions. After answering the last question, the 
console acknowledged the patient with a thank you and automatically transmitted the 
information over the phone line to the telemonitoring station. 
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Call center nurses performed twice-daily monitoring (morning and afternoon) of 
patients' weight and symptoms using the data transmitted through the telemonitoring 
system. When a patient's weight was acceptable and the patient was not symptomatic, 
monitoring continued without changes to therapy, and a summary report was sent to the 
appropriate physician's office. If a patient's weight was not within an acceptable range 
(i.e., it increased by more than 3-5 pounds in 2 days), the patient did not weigh in, or the 
patient was symptomatic, call center nurses called the patient or a nurse practitioner to 
alert them to the situation. The call center nurses would obtain further information from 
the patient and adjust the medical therapy or suggest an ER visit or hospital admission. 
In addition to periodic assessments, the intervention group participants received 
health education through weekly telephone calls from call center nurses. The nurses 
placed special emphasis on medication changes, changes in health status or condition, 
and the need for lifestyle modifications. Patients' physicians selected the telemonitoring 
and therapy parameters per individual patients' clinical status. 
All enrolled participants received standardized HF education and teaching 
materials irrespective of whether they were randomized to standard HF care or standard 
HF care plus telemonitoring. All patients received a comprehensive educational 
handbook, instructions about HF from registered nurses, and a diary with standardized 
instructions to record daily weight and symptoms. 
Per study protocol, participants were required to attend a follow-up visit at 6 
months for data collection for primary and secondary endpoints and for rerandomization. 
Participants were also required to attend a follow-up visit at 12 months for data collection 
for tertiary endpoints. At the 6-month protocol visit, after data collection, participants 
41 
who used the telemonitoring System were then rerandomized to continue telemonitoring 
or to standard care. If the participant was rerandomized to standard care therapy, he or 
she was provided with a digital home scale and instructed to obtain and record daily 
weight and HF symptoms in a diary. 
Due to the nature of the intervention, the intervention group was not blinded. 
This might have introduced some bias into the trial; however, the study group agreed that 
the design would maximize consistent HF baseline care for every patient independent of 
randomization, which would allow the group to determine the true clinical effect of 
telemonitoring. 
To minimize bias, research staff was blinded to the study hypothesis and group 
assignment. They obtained all data through the telephone (details are described in the 
Data Collection section). Similarly, event adjudication was determined by a clinical 
endpoint committee, which was blinded to the study group. 
Group 1: Standard Care 
Group 1 participants received a CHF standard care plan individualized through 
routine patient care provided by a primary care physician or cardiologist or both. Patients 
were given diaries to chart their daily weight and instructed to take the diary with them to 
each physician visit. 
Group 2: Standard Care Plus Technology-Driven HF Monitoring 
In addition to receiving the same CHF standard care that Group 1 received, Group 
2 participants were given a telemonitoring System to monitor their weight and symptoms 
daily through telephonic transmission of data. The data were used to alert caregivers or 
physicians and to reinforce HF management. 
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Data Collection 
All data were collected through standardized procedures and data collection 
instruments. Data coordination was perfonned at the Center for Epidemiology and 
Clinical Investigation Sciences, University of Louisville, under the direction of Dr. 
Carlton Hornung. CRCs at each site collected baseline data and administered the 6MWT 
at the time of enrollment and at 6 and 12 months after enrollment. Regardless of group, 
the patients were contacted every 6 weeks (i.e., at study weeks 6, 12, 18,30,36, and 42) 
by telephone to obtain supplemental data on social support assessment and any ER visits 
or hospitalizations. 
At 12 weeks and 36 weeks, additional data on QOL were collected through 
completion ofQOL questionnaires via telephone. Research staff who were blinded to the 
study hypotheses and the intervention group participants, collected all of the telephone 
survey data. The data collected included socio-demographic variables; social and family 
support; clinical status; physical, functional, and mental health status; subjective health 
rating; HRQOL; and satisfaction with care. After each telephonic contact, research 
assistants mailed additional diaries and a self-addressed stamped envelope to participants. 
After completion of 6 and 12 month protocol visits, research assistants reminded 
participants to return the diaries in the self-addressed envelope. Medicare utilization data 
were obtained through CMS service utilization files. 
The study endpoints were measured through standardized instruments used in 
earlier and ongoing studies, as mentioned in chapter 2. Functional capacity was assessed 
using the 6MWT. QOL for patients with chronic HF was measured using the MLHF 
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questionnaire. Social support assessment was performed using the Krause-Marchetti 
survey. 
Study Endpoints 
This sub-study was limited to a 6-month follow-up. The purpose ofthe sub-study 
was to evaluate the impact of adding telemonitoring to standard care on functional 
capacity (in terms of6MWD or 6MW) and QOL (MLHF score) at the study end point. 
Data Entry 
The HCF A HF Demonstration Project Study Group designed a customized 
computer-based system for data entry. The DCC created a separate database for each site 
with separate data entry files. Each site had access to its own data entry files but did not 
have access to the files at other sites. The site-specific CRCs collected and entered the 
data into electronic case report forms during each patient visit and telephone survey. 
CRC data transmissions were stored in a temporary database, and integrity of the 
data was verified against source documents using the quality assurance keys developed 
by the DCC. Separate and secure databases were created on a server at each site and 
were password protected; only authorized personnel had access to the data. The DCC 
prepared a standard manual of operations to guide CRCs and each clinical site monitoring 
team in order to maintain the quality and integrity of the data. 
Data Quality Monitoring 
Prior to the first month of study, standardized pre-study training sessions were 
held at the University of Pennsylvania for the principal investigators (PIs) and CRCs 
from all sites. These sessions were to train PIs and CRCs in all aspects of study protocol, 
methods, data collection, and data entry. The first line of data quality monitoring was 
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performed at the point of data collection. The second line was performed at the time of 
data entry. Only after completion of all pre-specified data fields were the files merged 
into a site-specific database. 
The computer data entry system had a built-in data quality/integrity check system, 
which verified the integrity and quality of the data at each site. The DCC maintained an 
800-number telephone hotline for CRCs to call with any questions with regard to data 
entry or editing. The DCC, project manager, and CRCs had weekly conference calls to 
identify and address data collection and quality problems. The director and the DCC 
conducted periodic reviews of the collected data and monitored the type and frequency of 
data entry errors, edits, and changes at each site. 
The DCC merged the electronic case report forms, telemonitoring System data, 
and CMS data for each site separately and created individual and site-specific data files 
for monitoring the quality of data and tracking of errors at each site. If a high error rate 
occurred at any site, notices were sent to the clinical site monitoring team and CRCs. 
The integrity of the data was verified with source documents, and errors were rectified at 
each site. 
Data Management 
The data coordination center was located in the Center for Epidemiology and 
Clinical Investigation Sciences at the University of Louisville (one of the sites of the 
project). The center had PhD-trained biostatisticians, epidemiologists, database 
management experts, a web master, and supporting personnel. Database management 
experts merged the data from individual sites and prepared a master data file for analysis. 
Sample Size and Power Calculations 
In the initial protocol, power analysis calculations were perfonned based on the 
primary end point of reduction in hospital admission rates. 
It was estimated that 175 patients per ann will be needed for the 6 month data 
collection period for a primary analysis, a total of 35% patients to detect a 40% 
reduction in cardiovascular hospital admission rates (two-sided alpha of 0.05, 
80% power, assuming a 6-month readmission rate for the control group 
(Krumholz 1997) of 35% and 21 % in the interventional ann. Assuming the 20% 
reduction in the sample size during the first 6 months, it was estimated that 220 
patients per ann, for total of 440 participants who meet all eligibility criteria and 
consent to enroll in the study. (HCF A Heart Failure Demonstration Project, 2000) 
According to a recent review published by A TS (2002), optimal reference 
equations for healthy population-based samples using standardized 6MWT methods were 
not yet available. Miyamoto et ai. (2000) conducted a study in which the median 6MWD 
was approximately 580 m for 117 healthy men and 500 m for 173 healthy women. 
Another study reported a mean 6MWD of 630 m in 51 healthy older participants (Stevens 
et aI., 1999). 
Cardiac rehabilitation in patients with various heart diseases increased the 6MWD 
by a mean of 170 m, or 15% (Bittner et aI., 1993). In an observational study of 45 older 
patients with HF, the smallest difference in 6MWD that was associated with a noticeable 
difference in the global rate of worsening was a mean of 43 m (O'Keffe et aI., 1998). 
However, there have not been any studies in the literature that defined the degree of 
change in 6MWD or 6MW and QOL from a baseline to the point of measurement and 
that should be considered clinically meaningful or as demonstrating clinically significant 
improvement or deterioration. Also, no randomized studies have found any correlation 
between clinically meaningful improvement or deterioration in 6MWD or 6MWW 
correlated with and clinically meaningful improvement or deterioration in QOL. 
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The focus of this sub-study is to define clinically meaningful cutoffs and use 
those cutoffs to estimate the efficacy of technology-driven HF management systems in 
improving the functional capacity and QOL for patients with chronic HF. Given 
extremely uncertain estimates of the cutoff values for the study variables, it is not 
possible to offer a specific power calculation. After obtaining the data, a post-hoc power 
analysis may be performed. As the intervention is not invasive and carries no risk, 
according to the available data (as mentioned in chapter 2), there is no clinical rationale 
to say that the telephonic management of patients with HF is inferior to standard care. 
Data Analysis 
SPSS version 17.0 soft ware was used for the data analysis. The primary analysis 
included all randomized patients using the principle of intent to treat (International 
Conference on Harmonization of Technical Requirement for Registration of 
Pharmaceuticals for Human Use, 1999). The randomized patients were excluded only 
upon objective detection of violation of eligibility criteria. In addition, the subset of 
participants who complied with the protocol were analyzed; compliance was determined 
by completion of at least 1 month of care under the treatment to which the participant was 
randomized, availability of the primary outcome, and absence of any major protocol 
violation. 
Handling of Missing Data 
Individual missing items can be a nuisance to statistical packages based on the 
assumption that balanced data are available. If records are deleted where individual items 
are missing, there may be both loss of power and bias in estimation. The reasons for 
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missing covariate data (e.g., refusal, problems with data collection, rehospitalization, and 
death) have been documented. 
Many statistical methods may be used to estimate or impute the most likely values 
for the missing items. If a patient died prior to the assessment or was hospitalized and 
not available for assessment, then 0 m was assigned for 6MWD; however, some ofthe 
patients who were hospitalized with CHF exacerbation were able to walk 0 to 25 feet (5-
10 m), which was considered significant impairment in functional capacity. Therefore, 
these patients were classified as members of a clinically meaningful deterioration in 
functional capacity group. 
The MLHF questionnaire consists of 21 items and three subscales measuring the 
following dimensions: (a) the physical function dimension (eight items), (b) the 
emotional function dimension (five items), and (c) an overall QOL score (all 21 items). 
Eight separate items not assessing an underlying construct or dimension of HQOL 
measure social and economic impairments for patients due to HF and are part of the 
overall score. To measure the effects of symptoms, functional limitations, and 
psychological distress on an individual's QOL, the MLHF questionnaire asks participants 
to indicate to what extent each of 21 facets prevented them from living as they desired 
using a 6-point (0 to 5) Likert scale. 
The MLHF questionnaire results in a total score between 0 (no impairment) and 
105 (severe impairment), which represents the physical, socioeconomic, and 
psychological impairments that affect QOL. The 6-point score is divided into three 
quartiles: The scores 0 and I belong to the first quartile (mild impairment); 2 and 3, the 
second quartile (moderate impairment); and 4 and 5, the third quartile (severe 
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impairment). For each question, a score of 5 was assigned to those patients who died 
prior to assessment, and a score of 4 was assigned to those patients who were hospitalized 
and not available for assessment. In both cases, the patients were classified into a 
clinically significant deteriorated group. 
If a participant filled in most of the questions on the MLHF questionnaire except 
for a few (not more than three), then the missing data were estimated using the multiple 
means imputation method (Curran et aI., 1998). The objective of imputation is to replace 
the missing data with estimated values to preserve the relationships between items and to 
reflect, to the extent possible, the most likely true value. The dropouts that were 
unrelated to outcomes were ignored in the analysis (Heyting, Tolboom, & Essers, 1992). 
Adjustment for Confounders 
Although participants were randomly assigned to intervention and control groups, 
there was a possibility of unequal distribution of patients due to potential confounders. 
Adjustment for covariates associated with the outcome is essential (Altman & Dore, 
1991; Hauck, Anderson, & Marcus, 1998; Senn, 1994). Therefore, baseline variables that 
were correlated with outcomes were included in multivariable models in the comparison 
of two groups. 
Potential variables are socio-demographic factors (age, gender, race/ethnicity, 
education); heart failure severity and case mix (ejection fraction, NYHA class, 
number of co-morbid conditions, pacemaker/I CD etc) and variables potentially 
associated with processes of care (primary care vs. cardiologist involvement in 
care). Confounding is assessed by a change in the effect size of treatment caused 
by inclusion of the potential confounder as a covariate. (HCFA Heart Failure 
Demonstration Project, 2000) 
Generalizability of Study Sample 
To facilitate interpretation of study findings and estimate the generalizability of 
findings, potentially eligible Medicare beneficiaries were screened for the study. Out of 
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those screened and found eligible were included in the study. Eligible enrollees were 
described in detail and compared to eligible non-enrollees according to all baseline data 
provided by the refusers. However, the measures of statistical significance for these 
comparisons were not reliable owing to the limited power. 
Preliminary Analyses 
Univariate 
Because of random assignment, the two groups were not expected to differ on any 
variable. If they differed on any variable related to an outcome or correlated highly with 
an outcome, its confounding effect was adjusted using the variable as a covariate in 
subsequent analyses. Univariate statistics (mean, median, SD, and SE) were computed 
for all quantitative variables; for all dichotomous variables, counts and percentages, along 
with SE, were computed. 
Bivariate 
Associations among all variables were examined for potential redundancy or 
colinearity for subsequent regression analysis. The method of assessing the association 
varied depending on the nature of the variables and the shape of their frequency 
distributions. If there was an association, then the variables were adjusted in subsequent 
analyses by stratification as covariates or by forced entry into regression equations. 
The effects of the intervention were statistically tested using independent sample 
1-tests, paired sample 1-tests, Mann-Whitney test, chi-square statistic, and Fisher's exact 
tests, which, in tum, depended on the nature of the outcome variable and the shape of its 
frequency distribution. 
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Analysis of Endpoints 
Integrated methods of distribution- and anchor-based methods were used. RTM is 
a statistical phenomenon that occurs when repeated measurements are made on the same 
subject or unit of observation (Barnett et aI., 2005). Values are observed with random 
error; it is rare to observe data without random error, which makes RTM a common 
phenomenon (Barnett et aI., 2005). RTM is a statistical phenomenon that may make 
natural variation in repeated data appear to be real change (Barnett et aI., 2005). The 
effect ofRTM in a sample becomes more noticeable when measurement error increases 
due to repeated measurements in the sample (Barnett et aI., 2005). 
Change over 6 months from the baseline was adjusted for RTM using the EN 
method (Edwards et aI., 1978; Speer et aI., 1992). Regression to the normative group 
mean was assessed by finding Spearman's or Pearson's correlation coefficients 
(depending on the distribution) between the baseline and 6-month measurements, 
between the baseline and change from the baseline to 6-month measure, and between the 
absolute difference between the baseline and normative mean and the baseline to 6-month 
change in measurement. If the R TM was significant, then the change from baseline to 6 
months was adjusted for RTM using the EN method. If the RTM was not significant, 
then the observed change from baseline to 6 months was taken into account without any 
adjustment. 
Adjustment for Regression to the Mean 
The EN method classifies pre-post intervention changes as improved or 
deteriorated based on 95% confidence intervals calculated using the EN index. If there 
51 
was RTM, an individual's true score or measurement would be closer to the mean of the 
group than to the actual pretest score or measurement (Barnett et aI., 2005). 
EN index = (f - X2)/SEM (2) 
where, t' is the true score or measurement 
f = rt(X1-MG) + MG (3) 
where, rt is the reliability coefficient of the measure or instrument, and MG is the 
mean of the normative group toward which the scores or measurements are 
assumed to regress (Crosby et aI., 2004). 
The EN CI is asymmetrical around the actual pretest score, whereas in the SEM 
method, the CI centers on the pretest score. 
To calculate the mean of the normative group, the sample was anchored to NYHA 
Class II, III, and IV groups by stratification. Normative group means, SD, and SEM were 
calculated for each group. Using the above formulae, each individual's true score, EN 
index, and 95% confidence interval around the true score were calculated to establish 
threshold values of cutoffs (true score ± 1.96* EN index). If the post-intervention score 
or measurement after 6 months fell beyond the cutoffs, then the change from the baseline 
was considered true change toward improvement or deterioration after adjusting for 
RTM. To define whether this change was clinically meaningful or not, the change was 
measured in terms ofSEM (i.e., true change after adjusting for RTM/SEM; see Figure 1). 
Standard Error of Measurement 
SEM was calculated using the formula SD* SQRT(l-rt), in which SD is the 
standard deviation of the baseline measurement and SQRT is the square root (Anstassi & 
Urbina, 1997; Redelmier et aI., 1997). If the magnitude of change from the baseline after 
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to the Mean 
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+ 1 SEM change 
Clinically meaningful 
improvement 
+ 1.96* ENindex 
No clinically meaningful change from baseline 
Figure 1. Adjustment of regression to the mean and calculation of clinically meaningful 
change. 
correction to RTM was greater than or equal to 1 SEM, then that change was defined as 
clinically meaningful (Wyrwich, Tierney, et aI., 1999). Based on the direction and 
magnitude of change in terms of +/- SEM units, individuals were grouped into clinically 
meaningful improvement, deterioration, or no change from baseline. 
Assessment of the Effect of Technology-Driven Heart Failure Management System 
Clinically meaningful change at the individual level was assessed by the SEM 
method after adjusting the change over time to RTM. The statistical significance of 
clinically meaningful change with respect to the standard care group and the standard 
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care plus telemonitoring group was tested through a chi-square statistic; odds ratios were 
calculated using a Mantle-Haenszel test. After defining groups with clinically 
meaningful improvement, deterioration, or no change in functional capacity or QOL, the 
group with no change was considered a reference group. 
Multinomial regression analysis was performed to establish the best predictors of 
clinically meaningful improvement and deterioration in functional capacity and QOL for 
patients with HF. Both the control group and intervention group were controlled for all 
possible potential confounders. Sensitivity and specificity of clinically meaningful 






A total of 284 participants who met eligibility criteria were randomized into either 
a standard care group C!! = 142) or a technology-driven HF management group (g = 142). 
Out of 142 participants in the standard care group, 36 were excluded from analysis due to 
missing data (1 was a Pacific Islander, 4 lacked baseline characteristics documentation, 6 
dropped out, 2 entered hospice, 2 suffered noncardiac deaths, and 21 were lost to follow-
up). Out of 142 participants in the technology-driven HF management group, 47 were 
excluded from analysis due to missing data (2 lacked baseline characteristics 
documentation, 11 dropped out, 2 entered hospice, 2 suffered noncardiac deaths, and 30 
were lost to follow-up). 
Baseline characteristics, such as demographic variables, cardiovascular risk 
factors, past medical history of cardiovascular diseases, and HF disease characteristics 
(see Table 4), of the sample included in the study (g = 201) were compared with those of 
the sample excluded from the analysis C!L = 83) due to loss to follow-up or missing 
information. The sample included in the analysis was not different from the group 
excluded from the analysis. Distribution of baseline characteristics in the standard 
medical care group and the technology-driven HF management group were tested. Tests 
of normality showed baseline target variables (6MWD, 6MW, MLHF total score, 
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emotional domain score, and physical domain score) were not normally distributed (see 
Figures 2-6 and Table 3). 
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Figure 2. Sample attrition. 
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Figure 5. Frequency distribution of MLHF scores at baseline. 
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Figure 7. Frequency distribution ofMLHF emotional dimension scores at baseline. 
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Table 3 
Tests of Normality for Baseline Target Variables 
Shapiro-Wilk Test 
Q.Q: 
Randomization Static df tailed) 
6MWD (baseline) Technology-driven .941 95 .000 
disease management 
Standard medical care .957 106 .002 
MLHF total score Technology-driven .965 95 .013 
(baseline) disease management 
Standard medical care .943 106 .000 
Physical domain score Technology-driven .950 95 .001 
(baseline) disease management 
Standard medical care .952 106 .001 
Emotional domain score Technology-driven .909 95 .000 
(baseline) disease management 
Standard medical care .862 106 .000 
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Estimation of Skewness and Kurtosis for Baseline Target Variable Distribution 
The skewness and kurtosis of frequency distributions in the baseline 6MWD, 
6MW, and QOL (MLHF) scores of the intervention vs. control groups were estimated 
(see Table 4). Kurtosis is a measure of the peakedness or flatness of a distribution. A 
kurtosis value near zero indicates a shape close to normal. A negative value indicates a 
distribution that is more peaked than normal, and a positive kurtosis indicates a shape that 
is flatter than normal. An extreme positive kurtosis indicates a distribution in which 
more of the values are located in the tails rather than around the mean. 
Skewness is the extent to which a distribution of values deviates from symmetry 
around the mean. A value of zero means the distribution is symmetric. A positive 
skewness indicates a greater number of smaller values, and a negative value indicates a 
greater number of larger values. 
In the Classic Principles of Statistics (1965), M.G. Bulmer suggests rule of 
thumbs. If skewness is less than -lor greater than + 1, the distribution is highly skewed. 
If skewness is between -1 and -Yz or between +Yz and + 1, the distribution is moderately 
skewed. If skewness is between -Yz and +Yz, the distribution is approximately 
symmetric. The reference standard is a normal distribution, which has a kurtosis of 3. In 
token of this, often the excess kurtosis is presented: excess kurtosis = kurtosis-3. A 
normal distribution has kurtosis exactly 3 (excess kurtosis exactly 0). Any distribution 
with kurtosis::::; 3 (excess::::; 0) is called mesokurtic. A distribution with kurtosis < 3 
(excess kurtosis < 0) is called platykurtic. Compared to a normal distribution, its central 
peak is lower and broader, and its tails are shorter and thinner. A distribution with 
kurtosis> 3 (~xcess kurtosis> 0) is called leptokurtic. Compared to a normal distribution, 
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its central peak is higher and sharper, and its tails are longer and fatter (Bulmer, 1965; see 
Table 4). 
Table 4 




MLHF total score 
Physical dimension score 
Emotional dimension score 
6-MWD 
6-MW 
MLHF total score 
Physical dimension score 

























Note. If the skewness or kurtosis statistic falls within the range of +/- 2 times the SE, 
then it falls within the expected range of chance fluctuations (Tabachnick & Fidell, 1996). 
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The 6MW, MLHF total score, and emotional dimension score were moderately 
skewed in both the standard care and technology-driven care groups, whereas the 6MWD 
values were skewed only in standard care group. 
Comparison of Baseline Characteristics 
The baseline characteristics of the intervention group receiving technology-driven 
HF management and the control group receiving standard medical care were analyzed 
using a chi-square test for equality of proportions or independent sample i-tests for 
equality of means or a Mann-Whitney (U) test, when appropriate. Both groups were well 
balanced with respect to their baseline characteristics, except for revascularization 
procedures (see Table 5). There was statistically significant difference between the 
standard care group and the technology-driven HF management group with respect to 
history of revascularization procedures. About 50% ofthe participants in the technology-
driven HF management group had undergone revascularization procedures, whereas in 
the standard medical care group, only 36% had undergone revascularization procedures 
(X2 = 4.409, df= 1, P = 0.036; see Table 5). 
Description of Target Variables After 6 Months 
Functional capacity (6MWD and 6MW) and QOL scores (MLHF scores) after 6 
months for the group receiving technology-driven HF management were compared with 
those of standard care group. The Mann-Whitney test statistic (U) and Z scores were 
calculated. There was no significant difference between the two groups after 6 months 





Standard driven HF 
care management ILvalue 
Characteristic ill = 106) ill = 95) (2-tailed) 
Demographic variables 
Age in years (Mean) 75 ±8 74±7 0.179 
BMI (Mean) 27±6 28 +6 0.183 
Gender 0.825 
Male (%) 59 58 
Female (%) 41 42 
Race 0.170 
Caucasians (%) 80 87 
Others (%) 20 l3 
Marital status 0.155 
Married (%) 50 60 
Unmarried (%) 50 40 
Cardiovascular risk factors 
Smoking (%) 38 31 0.294 
Hyperlipidemia (%) 60 63 0.686 
Hypertension (%) 76 80 0.539 
Diabetes (%) 44 40 0.534 
Peripheral vascular diseases (%) 22 27 0.350 
History of 
Cerebrovascular accident/transient 19 22 0.690 
ischemic attack (%) 
Myocardial Infarction (%) 46 48 0.756 
Revascularizations (%) 36 50 0.036a 
Valvular Abnormalities (%) 81 81 0.989 
Disease characteristics 
Duration ofHF in months (mean) 59 ±74 59 ±78 0.990 
Left Ventricular Ejection Fraction 32 ±14 32 +14 0.817 
(Mean) 
Type ofHF 
Systolic (%) 58 63 0.564 
Diastolic (%) l3 l3 1.000 
Systolic and diastolic (%) 28 24 0.526 
Type of Cardiomyopathy 0.458 
Ischemic (%) 49 54 
Non-ischemic (%) 51 46 
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Table 5 (continued) 
Technology-
Standard driven HF 
care management lLvalue 
Characteristic ili = 106) ili = 95) (2-tailed) 
NYHAClass 0.509 
II(%) 35 31 
III & IV (%) 65 69 
Disease management 
Cardiologist on board 75 69 0.380 
Pacemaker (%) 16 15 0.710 
ICD (%) 25 28 0.638 
Beta-blockers (%) 81 85 0.608 
ACE-I/ARBs (%) 93 88 0.217 
Target variables 
0.784b 6MWD in meters (mean) 226 +144 213 ±118 
6MW in kg/m (mean) 1793 t±12187 17225210768 0.877b 
MLHF total score (mean) 35 ±23 38 ±22 0.219b 
Emotional dimension score (mean) 7±7 8 +7 0.127
b 
Physical dimension score (mean) 17 ±11 18 ±11 0.216b 
aStatistically significant difference observed. bMann-Whitney (U) test. 
Table 6 





Target variable (mean) (mean) Mann-Whitney test 
U Z l2.G: 
tailed) 
6MWD(m) 189.14 189.16 5022 -0.320 0.975 
6 MW (kg/m of work) 15184.88 14342.54 3673 -0.538 0.590 
MLHF total score 39.00 38.00 4930 -0.255 0.799 
Physical domain score 18.50 17.90 5006 -0.069 0.945 
Emotional domain score 7.50 7.60 4649 -0.945 0.345 
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The mean ofthe changes in functional capacity and QOL scores after 6 months 
for the standard management group vs. the technology-driven HF management group 
were not statistically significant (see Table 7). 
Table 7 




Target variable group group 
mean change (mean) (mean) Mann-Whitney test 
U Z P.Q: 
tailed) 
6MWD(m) 33.48 20.44 4731.5 -0.737 0.461 
6 MW (kg/m of work) 2574.21 2482.28 3807.0 0.000 1.000 
MLHF total score -3.40 0.74 4814.0 -0.537 0.591 
Physical domain score -1.50 0.93 4577.5 -1.112 0.266 
Emotional domain score -0.84 0.27 4981.0 -0.132 0.895 
Correlations Among Changes in Target Variables After 6 Months 
After controlling for the treatment group assignment, the change in 6MWD after 6 
months was correlated with changes in 6MW (r.. = 0.892, Q.. < 0.01), MLHF total score (r.. = 
-0.537, p < 0.01), physical domain score (r = -0.492, P. < 0.01), and emotional domain 
score (r.. = -0.468, Q.. < 0.01) after 6 months. The change in 6MW after 6 months was also 
correlated with changes in MLHF total score (r = -0.418, Q.. < 0.01), physical domain 
score (r = -0.364, Q.. < 0.01), and emotional domain score (r = -0.350, Q.. < 0.01) after 6 
months. The change in physical domain score after 6 months was correlated with the 
change in emotional domain score after 6 months (r = 0.762, P. < 0.01). 
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Regression to the Mean 
R TM is a statistical phenomenon that occurs when repeated measurements are 
made on the same subject or unit of observation. R TM may make natural variation in 
repeated data appear to be real change. It is rare to observe data without random error, 
which makes RTM a common phenomenon (Barnett et aI., 2005). The effect ofRTM in 
a sample becomes more noticeable when measurement error increases due to repeated 
measurements in the sample. 
The scatter plot of change in target variables over 6 months against baseline 
measurements helped to identify RTM. The effect ofRTM should be adjusted with 
appropriate statistical techniques. The scatter plots of change in target variable from 
baseline to 6 months vs. the baseline target variable (e.g., 6MWD, 6MW, and QOL 
[MLHF total score]) are depicted in Figures 8-10. These scatter plots provide visual 
input on the effect of R TM on baseline target variables. 
Assessment of Regression to Mean 
Regression toward the normative mean was assessed by drawing partial 
correlations between baseline and 6-month measurements, between baseline 
measurements and change over 6 months, and between the absolute difference between 
baseline and normative group mean and the absolute difference between baseline and 6-
month measurements of target variables (6MWD, 6MW, MLHF total score, MLHF 
physical domain score, and MLHF emotional domain score). 
Regression to Mean for Change in 6-Minute Walk Distance Over 6 Months 
There were partial correlations between 6MWD at baseline and after 6 months (r 
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Figure 10. Scatter plot of change in MLHF total score (QOL) against baseline. 
months (r.. = 0.27, 2-< 0.01). The absolute difference between the baseline 6MWD and 
normative mean and the absolute difference between the baseline 6MWD and 6MWD 
after 6 months (r = 0.15, 2-< 0.01) were statistically significant, indicating that RTM for 
change in 6MWD after 6 months was statistically significant. 
Regression to Mean for Change in 6-Minute Work after 6 Months 
Pearson's correlations were made between 6MW at baseline and after 6 months (r 
= 0.73, Q < 0.01) and between baseline 6MW and change in 6MW after 6 months (r = 
0.30,2-< 0.01). The absolute difference between the baseline 6MW and normative mean, 
and the absolute difference between the baseline 6 MW and 6 MW after 6 months (r = 
0.28, P < 0.01) were statistically significant, indicating that RTM for change in 6MW 
after 6 months was statistically significant. 
69 
Regression to Mean for Change in MLHF Score after 6 Months 
Partial correlations were made between the MLHF total score at baseline and after 
6 months (r = 0.539, Q < 0.01) and the baseline MLHF total score and change in MLHF 
total score after 6 months (r = 0.25, I2.. < 0.01). The absolute difference between the 
baseline MLHF total score and the normative mean and the absolute difference between 
the baseline MLHF total score and the MLHF total score after 6 months (L= - 0.07, I2..= 
0.30) were statistically significant, indicating that RTM for change in MLHF total score 
from baseline to 6 months was statistically significant. 
These findings suggested that the effect of R TM on target variable measurements' 
at baseline and 6 months was statistically significant. Individuals with more severe 
impairment in functional capacity or QOL at baseline exhibited greater change from 
baseline to 6 months, and individuals with less impairment at baseline exhibited less 
change from baseline to 6 months. Therefore, the change in 6MWD, 6MW, MLHF total 
score, physical domain score, and emotional domain score from baseline to 6 months 
should be adjusted to RTM. 
Adjustment ofRTM for Change in Target Variables from Baseline to 6 Months 
If the regression toward the group's normative was is significant, then the 
differences between baseline and after 6 months values of target variables might have 
understated or overstated the true change. Therefore, target variable change from 
baseline to 6 months was adjusted to RTM using the EN method. According to the EN 
method, the change in target variables from baseline to 6 months was classified as 
improved, no change, or deteriorated based on confidence intervals calculated using 
SEM. The change in measurements over time was adjusted for regression to the mean by 
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establishing threshold values of +/-1.96* EN index (95% confidence interval) as cutoff 
values to determine real or true change from baseline. Then clinically meaningful change 
from baseline was calculated using SEM method (described later in this chapter; see 
Table 8). 
Table 8 




6MWD at baseline and after 6 months 
Baseline 6MWD and change in 6MWD after 6 months 
Absolute difference between baseline 6MWD and 
normative mean and absolute difference between baseline 
6MWD and 6MWD after 6 months 
6MW 
6MW at baseline and after 6 months 
Baseline 6MW and change in 6MW after 6 months 
Absolute difference between baseline 6MW and normative 
mean and absolute difference between baseline 6MW and 
6MW after 6 months 
QOL (MLHF) total score 
MLHF score at baseline and after 6 months 
Baseline MLHF score and change in MLHF score after 6 
months 
Absolute difference between baseline MLHF score and 
normative mean and absolute difference between baseline 
























For each participant, the EN index was calculated for each baseline measurement 
by using Equation 2. The true score or measurement at baseline was calculated using 
Equation 3. The normative group mean, SD, and SEM were calculated by anchoring the 
study group to NYHA Class II, III, or IV. To determine the magnitude of true change 
from the baseline, the cutoff values for change in target variables from baseline to 6 
months (95% confidence interval) were determined by calculating +1-1.96*(EN index). 
The cutoff values (95% confidence interval) to determine true change from the baseline 
values for 6MWD, MLHF total score, physical domain score, and emotional domain 
score were determined by calculating +1-1.96*(EN index) for each patient. 
Therefore, if the change in 6MWD, MLHF total score, physical domain score, and 
emotional domain score fell within the range of cutoff values +1-1.96*(EN index), then 
the change was not real and was due to the effect ofRTM. If the magnitude of change 
from the baseline to 6 months fell beyond the cutoff values, then the change was real 
after adjusting to RTM. 
Determination of Clinically Meaningful Change in Target Variables From Baseline to 6 
Months 
If the magnitude of change from the baseline cutoff values was greater than or 
equal to I SEM, then it was defined as clinically meaningful (Wyrwich et ai., 1996). 
Based on the direction and magnitude of change in terms of +I-SEM units, individuals 
were grouped according to clinically meaningful improvement, deterioration, or no 
change from the baseline. SEM was calculated using the formula SD* SQRT(l- rD, in 
which SD is standard deviation of the baseline measurement and SQRT is the square root 
(Anstasi et ai., 1997; Redelmier et ai., 1997). After adjusting the change from baseline to 
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RIM, the cutoff values for true change in the target variables from baseline to 6 months 
(6MWD, 6MW, MLHF total score, MLHF physical domain score, and MLHF emotional 
domain score) were determined in terms of +/-1 unit of SEM. 
If the magnitude of true change in the target variables fell beyond +/-1 unit of 
SEM, then it was clinically meaningful. If the magnitude of true change in target 
variables fell within the range of cutoff values (+/-1 SEM unit), then it was true change 
but not clinically meaningful. Change in 6MWD by 42 m (or 39 m-42 m), in 6MW by 
3,668 kg/m of work (or 3,063-3,820), in MLHF total score by 6.0 points (or 5.0-7.0), in 
physical domain by 4.0 points (or 3.0-4.0), and emotional domain by 2.0 points (or 2.0-
3.0) were considered clinically meaningful change in patients with chronic CHF (see 
Tables 9 and 10). 
Table 9 




Target variable Mean SD (rt) SEM 
6MWD(m) 220.43 133.00 0.90 42.06 
6MW (kg/m of work) 17326.28 14857.16 0.90 3667.61 
MLHF total score 36.70 23.22 0.93 6.14 
Physical domain score 17.55 11.12 0.89 3.69 
Emotional domain score 7.09 6.64 0.88 2.30 
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Table 10 





Target variable Mean SD (rt) SEM 
NYHA Class II 
6MWD(m) 307.74 125.21 0.90 39.59 
6MW (kg/m of work) 24968.17 11236.05 0.90 3553.15 
MLHF total score 26.74 19.91 0.93 5.27 
Physical domain score 12.00 9.54 0.89 3.16 
Emotional domain score 5.24 5.59 0.88 1.94 
NYHA Class III 
6MWD(m) 183.23 111.41 0.90 35.23 
6MW (kg/m of work) 14363.49 9688.37 0.90 3063.73 
MLHF total score 41.34 22.79 0.93 6.03 
Physical domain score 20.18 10.89 0.89 3.61 
Emotional domain score 7.8 6.76 0.88 2.34 
NYHA Class IV 
6MWD(m) 144.25 132.90 0.90 42.03 
6MW (kg/m of work) 11177.32 12090.92 0.90 3823.48 
MLHF total score 42.95 26.38 0.93 6.98 
Physical domain score 20.79 10.97 0.89 3.64 
Emotional domain score 9.16 8.09 0.88 2.80 
Clinically Meaningful Change in 6MWD for Standard Care Vs. Technology-Driven 
Disease Management 
Based on the direction and magnitude of change in terms of +/-1 SEM units for 
target variables, individuals were divided into three groups: (a) clinically meaningful 
improvement, (b) no change, and (c) clinically meaningful deterioration from the 
baseline. Participants who died from cardiovascular disease were included in the 
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deterioration group. In comparing the standard care vs. technology-driven HF 
management groups, there was no statistically significant difference with respect to 
clinically meaningful change in 6MWD after 6 months (see Table 11). 
Table 11 
Clinically Meaningful Change in 6MWD in Standard Care vs. Technology-Driven 
Disease Management 
Clinically meaningful change in Total 
6MWD 
Deterio- No Improved 
rated change 
Randomi- Technology Count 21 41 33 95 
zation driven- % within 22.1% 43.2% 34.7% 100.0% 
disease randomi-
management zation 
Standard Count 21 45 40 106 
medical care % within 19.8% 42.5% 37.7% 100.0% 
randomi-
zation 
Total Count 42 86 73 201 
% within 20.9% 42.8% 36.3% 100.0% 
randomi-
zation 
Note. X2 = 0.256, df = 2, 12 (2-tailed) = 0.880. 
Addition of technology-driven teiemonitoring to standard therapy didn't provide 
any additional clinically meaningful impact on functional capacity measured in terms of 
6-MWD. After stratification of both groups into NYHA Class II and Class III/IV, the 
effect oftelemonitoring was still not significant (see Table 12). 
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Table 12 
Clinically Meaningful Change in 6MWD for Standard Care vs. Technology-Driven 
Disease Management After Stratification 
NY Clinically meaningful Total 
HA change in 6MWD 
clas Deteri- No Im-
s orated change ~roved 
III & Randomi- Technology Count 15 28 23 66 
IV zation driven- % within 22.7% 42.4% 34.8% 100.0% 
disease randomi-
management zation 
Standard Count 14 32 23 69 
medical care % within 20.3% 46.4% 33.3% 100.0% 
randomi-
zation 
Total Count 29 60 46 135 
% within 21.5% 44.4% 34.1% 100.0% 
randomi-
zation 
II Randomi- Technology Count 6 13 10 29 
zation driven- % within 20.7% 44.8% 34.5% 100.0% 
disease randomi-
management zation 
Standard Count 7 13 17 37 
medical care % within 18.9% 35.1% 45.9% 100.0% 
randomi-
zation 
Total Count 13 26 27 66 
% within 19.7% 39.4% 40.9% 100.0% 
randomiz 
ation 
Note. For NYHA Class II, X2 = 0.235, df= 2, and IL(2-tailed) = 0.889. For NYHA 
Classes III and IV, X2 = 0.936, df= 2, and Q (2-tailed) = 0.626. 
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Clinically Meaningful Change in 6MW from Baseline to 6 Months for Standard Care V s. 
Technology-Driven Disease Management 
In comparing standard care and technology-driven disease management groups, 
there was no statistically significant difference with respect to clinically meaningful 
change in 6MW after 6 months (see Table 13). Addition of technology-driven 
telemonitoring to standard medical therapy didn't provide any additional clinically 
meaningful benefits in tenns of functional capacity as measured by 6MW. After 
stratification of both groups into NYHA Class II and Class III/IV, the effect of 
telemonitoring was still not significant (see Table 14). 
Table 13 
Clinically Meaningful Change in 6MW for Standard Care vs. Technology-Driven 
Disease Management 
Clinically meaningful change Total 
in6MW 
Deteri- No Im-
orated change Qroved 
Randomi- Technology Count 16 38 26 80 
zation driven- % within 20.0% 47.5% 32.5% 100.0% 
disease randomization 
management 
Standard Count 18 43 33 94 
medical care % within 19.1% 45.7% 35.1% 100.0% 
randomization 
Total Count 34 81 59 174 
% within 19.5% 46.6% 33.9% 100.0% 
randomization 
Note. X2 = 0.131, df= 2, Q (2-tailed) = 0.937. 
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Table 14 
Clinically Meaningful Change in 6MW for Standard Care vs. Technology-Driven Disease 
Management After Stratification 
NYHA Clinically meaningful Total 
class change in 6 MW 
Deterio No Im-
-rated change .Qroved 
III Randomization Technology Count 11 25 20 56 
& driven- % within 19.6% 44.6% 35.7% 100.0% 
IV disease randomization 
management 
Standard Count 13 31 20 64 
medical care % within 20.3% 48.4% 31.3% 100.0% 
randomization 
Total Count 24 56 40 120 
% within 20.0% 46.7% 33.3% 100.0% 
randomization 
II Randomization Technology Count 5 13 6 24 
driven- % within 20.8% 54.2% 25.0% 100.0% 
disease randomization 
management 
Standard Count 5 12 13 30 
medical care % within 16.7% 40.0% 43.3% 100.0% 
randomization 
Total Count 10 25 19 54 
% within 18.5% 46.3% 35.2% 100.0% 
randomization 
Note. For NYHA Class II, X2 = 1.463, df = 2, and IL(2-tailed) = 0.481. For NYHA Class 
III and IV, X2 = 1.186, df= 2, and IL(2-tailed) = 0.359. 
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Clinically Meaningful Change in QOL From Baseline to 6 Months for Standard Care Vs. 
Technology-Driven Disease Management 
In comparing standard care and technology-driven disease management, there was 
no statistically significant difference with respect to clinically meaningful change in 
MLHF total score after 6 months (see Table 15). Addition of technology-driven 
telemonitoring to standard medical therapy didn't provide any additional clinically 
meaningful benefit for QOL measured in terms of MLHF score. After stratification of 
both groups into NYHA Class II and Class III/IV, the effect of telemonitoring was still 
not significant (see Table 16). 
Table 15 
Clinically Meaningful Change in MLHF Total Score for Standard Care vs. Technology-
Driven Disease Management 
Clinically meaningful change Total 
in MLHF total score 
Deteri- No Improved 
orated change 
Randomization Technology Count 38 30 27 95 
driven- % within 40.0% 31.6% 28.4% 100.0 
disease randomization % 
management 
Standard Count 30 46 30 106 
medical care % within 28.3% 43.4% 28.3% 100.0 
randomization % 
Total Count 68 76 57 201 
% within 33.8% 37.8% 28.4% 100.0 
randomization % 
Note. X2 = 3.877, df= 2, 2 (2-tailed) = 0.144. 
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Table 16 
Clinically Meaningful Change in MLHF Total Score for Standard Care vs. Technology-
Driven Disease Management After Stratification 
NYHA Clinically meaningful change Total 
Class in MLHF total score 
Deteri- No Im-
orated change 12roved 
III Randomi- Technology Count 24 21 21 66 
& zation driven- % within 36.4% 31.8% 31.8% 100.0% 
IV disease randomization 
management 
Standard Count 20 30 19 69 
medical care % within 29.0% 43.5% 27.5% 100.0 
randomization % 
Total Count 44 51 40 135 
% within 32.6% 37.8% 29.6% 100.0 
randomization % 
II Randomization Technology Count 14 9 6 29 
driven- % within 48.3% 31.0% 20.7% 100.0 
disease randomization % 
management 
Standard Count 10 16 11 37 
medical care % within 27.0% 43.2% 29.7% 100.0 
randomization % 
Total Count 24 25 17 66 
% within 36.4% 37.9% 25.8% 100.0 
randomization % 
Note. For NYHA Class II, X2 = 3.174, df= 2, and p (2-tailed) = 0.205. For NYHA 
Class III and IV, X2 = 1.986, df = 2, and n...(2-tailed) = 0.370. 
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Clinically Meaningful Change in Physical Domain Score from Baseline to 6 Months for 
Standard Care Vs. Technology-Driven Disease Management 
In comparing standard care vs. technology-driven disease management, there was 
no statistically significant difference with respect to clinically meaningful change in 
MLHF physical dimension score after 6 months (see Table 17). Addition of technology-
driven telemonitoring to standard medical therapy didn't provide any additional clinically 
meaningful benefit for the physical domain of MLHF score. After stratification of both 
groups into NYHA Class II and Class III/IV, the effect of telemonitoring was still not 
significant (see Table 18). 
Table 17 
Clinically Meaningful Change in MLHF Physical Domain Score for Standard Care vs. 
Technology-Driven Disease Management 
Clinically meaningful change Total 
in 12hysical domain score 
Deteri- No Improved 
orated change 
Randomi- Technology Count 19 61 15 95 
zation driven- % within 20.0% 64.2% 15.8% 100.0% 
disease randomization 
management 
Standard Count 18 71 17 106 
medical care % within 17.0% 67.0% 16.0% 100.0% 
randomization 
Total Count 37 l32 32 201 
% within 18.4% 65.7% 15.9% 100.0% 
randomization 
Note. X2 = 0.309, df= 2, 2 (2-tailed) = 0.857. 
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Table 18 
Clinically Meaningful Change in MLHF Physical Domain Score for Standard Care vs. 
Technology-Driven Disease Management After Stratification 
NYHA Clinically meaningful Total 
Class change in physical domain 
score 
Deterio- No Im-
rated change J2roved 
III Randomi- Technology Count 15 41 10 66 
& zation driven- % within 22.7% 62.1% 15.2% 100.0% 
IV disease randomization 
management 
Standard Count 15 42 12 69 
medical care % within 21.7% 60.9% 17.4% 100.0% 
randomization 
Total Count 30 83 22 135 
% within 22.2% 61.5% 16.3% 100.0% 
randomization 
II Randomi- Technology Count 4 20 5 29 
zation driven- % within 13.8% 69.0% 17.2% 100.0% 
disease randomization 
management 
Standard Count 3 29 5 37 
medical care % within 8.1% 78.4% 13.5% 100.0% 
randomization 
Total Count 7 49 10 66 
% within 10.6% 74.2% 15.2% 100.0% 
randomization 
Note. For NYHA Class II, X2 = 0.839, df= 2, and Q...(2-tailed) = 0.658. 
III and IV, X2 = 0.127, df= 2, and I!..(2-tailed) = 0.938. 
For NYHA Class 
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Clinically Meaningful Change in MLHF Emotional Domain Score From Baseline to 6 
Months for Standard Care Vs. Technology-Driven Disease Management 
In comparing standard care and technology-driven disease management, there was 
no statistically significant difference with respect to clinically meaningful change in 
MLHF emotional dimension score after 6 months (see Table 19). Addition of technology 
driven telemonitoring to standard medical therapy didn't provide any additional clinically 
meaningful benefit for the emotional domain of MLHF score. After stratification of both 
groups into NYHA Class II and Class IIIIIV, the effect of telemonitoring was still not 
significant (see Table 20). 
Table 19 
Clinically Meaningful Change in MLHF Emotional Domain Score for Standard Care vs. 
Technology-Driven Disease Management 
Randomization Technology Count 









Note. X2 = 0.762, df = 2, 12..(2-tailed) = 0.683 
Table 20 
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Clinically meaningful Total 
change in emotional domain 
score 
Deteri- No Im-
orated change Qroved 
5 87 3 95 
5.3% 91.6% 3.2% 100.0% 
6 94 6 106 
5.7% 88.7% 5.7% 100.0% 
11 181 9 201 
5.5% 90.0% 4.5% 100.0% 
Clinically Meaningful Change in MLHF Emotional Domain Score for Standard Care 
Group vs. Technology-Driven Disease Management After Stratification 
NYHA Clinically meaningful Total 
Class change in emotional 
domain score 
Deteri- No Im-
orated change Eroved 
III Randomi- Technology Count 4 59 3 66 
& zation driven- % within 6.1% 89.4% 4.5% 100.0% 
IV disease randomization 
management 
Standard Count 6 57 6 69 
medical care % within 8.7% 82.6% 8.7% 100.0% 
randomization 
Total Count 10 116 9 135 
% within 7.4% 85.9% 6.7%100.0% 
randomization 
II Randomi- Technology Count 1 28 29 
zation driven- % within 3.4% 96.6% 100.0% 
disease randomization 
management 
Standard Count 0 37 37 
medical care % within .0% 100.0% 100.0% 
randomization 
Total Count 1 65 66 
% within 1.5% 98.5% 100.0% 
randomization 
Note. For NYHA Class II, X2 = 1.295, df= 2" and JL(2-tailed) = 0.439. For NYHA 
Class III and IV, X2 = 1.368, df = 2, and JL(2-tailed) = 0.504. 
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Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful Similar 
Directional Change in MLHF Score 
1. Clinically meaningful improvement in 6MWD to predict clinically meaningful 
improvement in MLHF score: sensitivity = 56.1 %, specificity = 71.5%, positive 
predictive value = 43.8%, negative predictive value = 80.5%, agreement = 67%. 
2. Clinically meaningful deterioration in 6MWD to predict clinically meaningful 
deterioration in MLHF score: sensitivity = 35.3 %, specificity = 86.5%, positive 
predictive value = 57.1 %, negative predictive value = 72.3%, agreement = 69%. 
3. No clinically meaningful change in 6MWD to predict no clinically meaningful 
change in MLHF score: sensitivity = 44.7 %, specificity = 58.4%, positive 
predictive value = 39.5%, negative predictive value = 63.4%, agreement = 53.2% 
(see Table 21). 
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful Similar 
Directional Change in MLHF Physical Domain Score 
1. Clinically meaningful improvement in 6MWD to predict clinically meaningful 
improvement in MLHF physical domain score: sensitivity = 68.8%, specificity = 
69.8%, positive predictive value = 30.1 %, negative predictive value = 92.2%, 
agreement = 69.7%. 
2. Clinically meaningful deterioration in 6MWD to predict clinically meaningful 
deterioration in MLHF physical domain score: sensitivity = 35.1 %, specificity = 
82.3%, positive predictive value = 31.0%, negative predictive value = 85.0%, 
agreement = 73.6%. 
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Table 21 
Clinical Meaningful Change in 6MWD vs. Clinically Meaningful Change in MLHF Total 
Score 
Clinically meaningful change in MLHF Total 
total score 
Deteriorated No Improved 
chan~e 
Clinically meaningful Deteriorated 24 15 3 42 
change in 6MWD 57.1% 35.7% 7.1% 100.0% 
No change 30 34 22 86 
34.9% 39.5% 25.6% 100.0% 
Improved 14 27 32 73 
19.2% 37.0% 43.8% 100.0% 
Total 68 76 57 201 
33.8% 37.8% 28.4% 100.0% 
Note. X2 = 24, df= 4, 12 < 0.001; Spearman correlation = 0.345, 12 < 0.001; Kappa = 
0.169,12< 0.001. 
3. No clinically meaningful change in 6MWD to predict no clinically meaningful 
change in MLHF physical domain score: sensitivity = 46.2 %, specificity = 
63.8%, positive predictive value = 71.0%, negative predictive value = 38.3%, 
agreement = 52.2% (see Table 22). 
Clinically Meaningful Change in 6MWD to Predict Clinically Meaningful Similar 
Directional Change in MLHF Emotional Domain Score 
1. Clinically meaningful improvement in 6MWD to predict clinically meaningful 
improvement in MLHF emotional domain score: sensitivity = 100%, specificity = 
66.7%, positive predictive value = 12.3%, negative predictive value = 100%, 
agreement = 68.1 %. 
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Table 22 
Clinically Meaningful Change in 6MWD vs. Clinically Meaningful Change in Physical 
Dimension Score 
Clinically meaningful change in physical Total 
domain score 
Deteriorated No Improved 
change 
Clinically Deteriorated 13 27 2 42 
meaningful change in 31.0% 64.3% 4.8% 100.0% 
6MWD No change 17 61 8 86 
19.8% 70.9% 9.3% 100.0% 
Improved 7 44 22 73 
9.6% 60.3% 30.1% 100.0% 
Total 37 132 32 201 
18.4% 65.7% 15.9% 100.0% 
Note. X2 = 22.37, df = 4, IL < 0.001; Spearman correlation = 0.31, Q < 0.001; Kappa = 
0.161, Q < 0.001. 
2. Clinically meaningful deterioration in 6MWD to predict clinically meaningful 
deterioration in MLHF emotional domain score: sensitivity = 63.6%, specificity = 
81.6%, positive predictive value = 16.7%, negative predictive value = 97.5%, 
agreement = 80.6%. 
3. No clinically meaningful change in 6MWD to predict no clinically meaningful 
change in MLHF emotional domain score: sensitivity = 45.3 %, specificity = 
80%, positive predictive value = 95%, negative predictive value = 14%, 
agreement = 49% (see Table 23). 
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Table 23 
Clinically Meaningful Change in 6MWD vs. Clinically Meaningful Change in Emotional 
Dimension Score 
Clinically meaningful change in Total 
emotional domain score 
Deteriorated No Improved 
change 
Clinically Deteriorated 7 35 0 42 
meaningful change 16.7% 83.3% .0% 100.0% 
in6MWD No change 4 82 0 86 
4.7% 95.3% .0% 100.0% 
Improved 0 64 9 73 
.0% 87.7% 12.3% 100.0% 
Total 11 181 9 201 
5.5% 90.0% 4.5% 100.0% 
Note. X2 = 30.02, df= 4,.Q.. < 0.001; Spearman correlation = 0.35, II < 0.001; Kappa = 
0.127, II < 0.001. 
Clinically Meaningful Change in 6MW to Predict Clinically Meaningful Similar 
Directional Change in MLHF Score 
1. Clinically meaningful improvement in 6MW to predict clinically meaningful 
improvement in MLHF score: sensitivity = 56%, specificity = 75%, positive 
predictive value = 47.5%, negative predictive value = 81 %, agreement = 69.5%. 
2. Clinically meaningful deterioration in 6MW to predict clinically meaningful 
deterioration in MLHF score: sensitivity = 32.8 %, specificity = 87%, positive 
predictive value = 56%, negative predictive value = 72%, agreement = 69%. 
3. No clinically meaningful change in 6MW to predict no clinically meaningful 
change in MLHF score: sensitivity = 53 %, specificity \= 57.4%, positive 
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predictive value = 43.2%, negative predictive value = 66.7%, agreement = 55.7% 
(see Table 24). 
Table 24 
Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in MLHF 
Score 
Clinically meaningful change in MLHF Total 
total score 
Deteriorated No Improved 
change 
Clinically meaningful Deteriorated 19 13 2 34 
change in 6MW 55.9% 38.2% 5.9% 100.0% 
No change 26 35 20 81 
32.1% 43.2% 24.7% 100.0% 
Improved 13 18 28 59 
22.0% 30.5% 47.5% 100.0% 
Total 58 66 50 174 
33.3% 37.9% 28.7% 100.0% 
Note. X2 = 22.8, df= 4, n... < 0.001; Spearman correlation = 0.33, Q < 0.001; Kappa = 
0.200, Q < 0.001. 
Clinically Meaningful Change in 6MW to Predict Clinically Meaningful Similar 
Directional Change in MLHF Physical Domain Score 
1. Clinically meaningful improvement in 6MW to predict clinically meaningful 
improvement in MLHF physical domain score: sensitivity = 69.3%, specificity = 
72.3%, positive predictive value = 30.5%, negative predictive value = 93%, 
agreement = 72%. 
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2. Clinically meaningful deterioration in 6MW to predict clinically meaningful 
deterioration in MLHF physical domain score: sensitivity = 34.4 %, specificity = 
83.4%, positive predictive value = 32.5%, negative predictive value = 85.0%, 
agreement = 74.7%. 
3. No clinically meaningful change in 6MW to predict no clinically meaningful 
change in MLHF physical domain score: sensitivity = 51 %, specificity = 62%, 
positive predictive value = 73%, negative predictive value = 38.7%, agreement = 
54.6% (see Table 25). 
Table 25 
Clinically Meaningful Change in 6MW vs. Clinically Meaningful Change in Physical 
Dimension Score 
Clinically meaningful change in physical Total 
domain score 
Deteriorated No Improved 
change 
Clinically Deteriorated 11 22 1 34 
meaningful change 32.4% 64.7% 2.9% 100.0% 
in6MW No change 15 59 7 81 
18.5% 72.8% 8.6% 100.0% 
Improved 6 35 18 59 
10.2% 59.3% 30.5% 100.0% 
Total 32 116 26 174 
18.4% 66.7% 14.9% 100.0% 
Note. X2 = 21.7, df= 4,.Q... < 0.001; Spearman correlation = 0.32, Q < 0.001; Kappa = 
0.l8, Q < 0.001. 
90 
Clinically Meaningful Change in 6MW to Predict Clinically Meaningful Similar 
Directional Change in MLHF Emotional Domain Score 
1. Clinically meaningful improvement in 6MW to predict clinically meaningful 
improvement in MLHF emotional domain score: sensitivity = 89%, 
specificity = 69%, positive predictive value = 13.6%, negative predictive 
value = 99%, agreement = 70%. 
2. Clinically meaningful deterioration in 6MW to predict clinically meaningful 
deterioration in MLHF emotional domain score: sensitivity = 45.4%, 
specificity = 82%, positive predictive value = 14.7%, negative predictive 
value = 95.7%, agreement = 80%. 
3. No clinically meaningful change in 6MW to predict no clinically meaningful 
change in MLHF emotional domain score: sensitivity = 48.7 %, specificity = 
70%, positive predictive value = 92.6%, negative predictive value = 15%, 
agreement = 51 % (see Table 26). 
Agreement Between NYHA Class and 6MWD in Assessing the Severity of Heart Failure 
Of participants, 4% had mildly impaired functional capacity, but 33% were 
classified under NYHA Class II. Only 25% had moderately impaired functional capacity, 
but 58% were classified under NYHA Class III. For 71 % of the participants functional 
capacity was severely impaired, but only 10% were classified under NYHA Class IV. 
Objectively measured functional capacity in terms of 6MWD was weakly correlated with 
physician-assessed severity (NYHA class) ofHF condition (spearman correlation (S) = 
0.365,12.< 0.05). The agreement between these two methods was very poor (18%) and 
not statistically significant (Kappa = -0.38, Q...= 0.173; see Table 27). 
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Table 26 
Clinically Meaningful Change in 6MW V s. Clinically Meaningful Change in Emotional 
Dimension Score 
Clinically meaningful change in Total 
emotional domain score 
Deteriorated No Improved 
change 
Clinically Deteriorated 5 29 0 34 
meaningful change 14.7% 85.3% .0% 100.0% 
in6MW No change 5 75 1 81 
6.2% 92.6% 1.2% 100.0% 
Improved 1 50 8 59 
1.7% 84.7% 13.6% 100.0% 
Total 11 154 9 174 
6.3% 88.5% 5.2% 100.0% 
Note. X2 = 18.28, df = 4, 1L < 0.001; Spearman correlation = 0.293, 12 < 0.001; Kappa = 
0.114, 12 < 0.001. 
Table 27 
Agreement Between NYHA Class and Functional Ca12acity 
6MWD at baseline Total 
>450m 301-450 m <300m 
NYHA class at II Count 7 29 30 66 
baseline %of 3.5% 14.4% 14.9% 32.8% 
total 
III Count 1 17 98 116 
%of .5% 8.5% 48.8% 57.7% 
total 
IV Count 0 4 15 19 
%of .0% 2.0% 7.5% 9.5% 
total 
Total Count 8 50 143 201 
%of 4.0% 24.9% 71.1% 100.0 
total % 
Note. X2 = 34.68, df= 1,12 < 0.05; Kap12a = -0.038, 1L = 0.173; agreement = 18%. 
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There is lack of agreement between objective assessment ofNYHA functional 
class and objective measuring of functional capacity because either patients or physicians 
are under- or over-estimating functional capacity compared to objectively measured 
values. The method of assessing NYHA class is arbitrary, and intraoperator variability is 
66% (Claire et aI., 2007). When assessing NYHA class, many clinicians simply ask 
patients with HF exertion symptoms how far they can walk or exert themselves before 
symptom onset. 
On the other hand, 6MWD (measured in meters) may not be a sole indicator of 
severity of CHF condition, especially when comparing individuals with different ages, 
genders, BMls, and comorbid conditions. The NYHA system and 6MWD are regularly 
used as outcome measures in clinical trials and are even included in HF management 
guidelines. Thus, the lack of agreement and consistency between these two classification 
methods suggests the need for development of novel classification methods by designing 
norm-referenced equations comprising age, gender, BMI, comorbid conditions, 
symptoms, and signs of HF. 
Predictors of Clinically Meaningful Change in 6MWD 
Clinically relevant independent variables were selected from baseline 
characteristics to predict 6MWD. These variables were age, BMI, ejection fraction, 
history of diabetes, history of coronary artery disease, history of coronary 
revascularizations, history of peripheral vascular disease, diastolic HF, beta-blocker 
usage, ACE/ARBs usage, history of ICD implantation, and telemonitoring usage. 
Multinomial logistic regression analysis was performed by entering variables through an 
entry method into the main effects model. The category of participants with no 
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meaningful change in 6MWD was selected as the reference category. Multinomial 
regression analysis was performed on 181 participants (20 were missing data; see Table 
28). 
The probability ofthe model's chi-square (X2 = 48.699, df= 24, II = 0.002) was 
statistically significant (ll < 0.05). The null hypothesis that there was no difference 
between the model without independent variables and the model with independent 
variables was rejected. The existence of a relationship between the independent variables 
and the dependent variable was supported (see Table 29). 
The benchmark to characterize this multinomial logistic regression model as 
useful was a 25% improvement over the rate of accuracy achievable by chance alone. 
The proportional by-chance accuracy rate was computed by calculating the proportion of 
cases for each group (improved, deteriorated, and no change) based on the number of 
cases in each group in the marginal percentages of the case processing summary, as 
previously described, and then squaring and summing the proportion of cases in each 
group: 0.3772 + 0.2102 + 0.1712. The proportional by-chance accuracy criterion was 
44.5% % (1.25 x 35.6% = 44.5%). The classification accuracy rate ofthis model should 
be greater than the proportional by chance accuracy criterion of 44.5%. 
The chi-square statistic was the difference in -2 log likelihoods between the final 
model and a reduced model. The reduced model was formed by omitting an effect from 
the final model. The null hypothesis was that all parameters of that effect are zero. The 
reduced model was equivalent to the final model because omitting the effect did not 
increase the degrees of freedom. The likelihood ratio tests for BMI, ejection fraction, 
history of diabetes, beta-blocker usage were statistically significant (Q < 0.05) and 
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Table 28 
Case Processing Summary for Predictors of Clinically Meaningful Change in 6MWD 
N Marginal ~ercentage 
Clinically meaningful Improved 68 37.6% 
change in 6MWD Deteriorated 38 21.0% 
No change 75 41.4% 
Diabetes mellitus-II Yes 75 41.4% 
(DM-II) No 106 58.6% 
History of CAD Yes 139 76.8% 
No 42 23.2% 
Revascularization Yes 77 42.5% 
procedures No 104 57.5% 
Peripheral vascular disease Yes 45 24.9% 
(PVD) No 136 75.1% 
Diastolic HF Yes 25 13.8% 
No 156 86.2% 
Beta-blocker usage Yes 150 82.9% 
No 31 17.1% 
ACE-I1ARBs usage Yes 165 91.2% 
No 16 8.8% 
ICD implantation Yes 53 29.3% 
No 128 70.7% 
Randomization Technology-driven disease 
82 45.3% 
management 
Standard medical care 99 54.7% 
Valid 181 100.0% 
Missing 20 
Total 201 
Sub,Qo,Qulation 181 a 
aThe dependent variable had only one value observed in 181 (100.0%) subpopulations. 
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Table 29 










Likelihood ratio tests 
Chi-square df 
48.699 24 .002 
suggestive of significant prediction of clinically meaningful change in 6MWD (see Table 
30). 
BMI, L VEF, diabetes, and beta-blocker usage were significant predictors for 
differentiating clinically meaningful improvement in 6MWD vs. no clinically meaningful 
change in 6MWD, whereas beta-blocker usage was the only variable significant enough 
to differentiate clinically meaningful deterioration in 6MWD vs. no clinically meaningful 
change in 6MWD (see Table 31). 
The classification accuracy for clinically meaningful improvement in 6MWD was 
65% and for no meaningful change in 6MWD, was 69%. The classification accuracy for 
clinically meaningful deterioration in 6MWD was 16%. The overall prediction accuracy 
ofthis model was 56.4%, which was greater than that of classification accuracy by 
chance alone (i.e., 44.5%; see Table 32). Therefore, this prediction model was valid to 
predict clinically meaningful change in 6MWD. 
Predictors of Clinically Meaningful Change in 6MW 
Clinically relevant independent variables were selected from baseline 
characteristics to predict 6MW. The variables included age, BMI, ejection fraction, 
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Table 30 
Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in 6MWD 
Model-fitting 
criteria Likelihood ratio tests 
-2 log 
Effect likelihood Chi-sguare df Sig. 
Intercept 3.352E2 .000 0 
Age 337.427 2.203 2 .332 
Body-mass index 346.897 11.673 2 .003 
(BMI) 
Left ventricular 348.680 13.456 2 .001 
ejection fraction 
(LVEF) 
Diabetes mellitus-II 342.222 6.998 2 .030 
(DM-II) 
History of CAD 336.610 1.386 2 .500 
History of 337.002 1.778 2 .411 
Revascularizations 
History of 336.134 .910 2 .635 
peripheral vascular 
disease (PVD) 
Diastolic HF 339.441 4.217 2 .121 
Beta-blocker usage 341.963 6.739 2 .034 
ACE-I1ARBs usage 336.529 1.306 2 .521 
History ofICD 340.091 4.867 2 .088 
implantation 
T elemonitoring 336.757 1.533 2 .465 
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Table 31 
Parameter Estimates for Predictors of Clinically Meaningful Change in 6MWD 
95% confidence 
interval for eXEb 
Clinically meaningful Lower Upper 
change in 6MWDa B SE Wald Sig. Expb bound bound 
Improved Intercept 10.246 3.295 9.671 .002 
Age -.045 .031 2.136 .144 .956 .901 1.015 
BMI -.134 .042 9.919 .002 .875 .805 .951 
LVEF -.071 .020 12.307 .000 .932 .896 .969 
DM-II .824 .411 4.026 .045 2.281 1.019 5.103 
CAD -.578 .505 1.307 .253 .561 .208 1.511 
Revasculari - -.437 .429 1.039 .308 .646 .278 1.497 
zation 
PVD .346 .429 .653 .419 1.414 .610 3.276 
Diastolic HF 1.650 .845 3.809 .051 5.205 .993 27.280 
Beta-blocker -1.241 .573 4.695 .030 .289 .094 .888 
usage 
ACE-I1ARBs -.269 .652 .170 .680 .764 .213 2.740 
usage 
ICD implanta- .774 .436 3.148 .076 2.169 .922 5.100 
tion 
T e1emonitoring -.176 .401 .193 .660 .839 .382 1.839 
Deterior- Intercept 2.900 3.435 .713 .398 
ated Age -.016 .033 .225 .635 .985 .923 1.050 
BMI -.026 .041 .396 .529 .975 .900 1.056 
LVEF -.033 .021 2.387 .122 .967 .927 1.009 
DM-II -.341 .475 .515 .473 .711 .280 1.805 
CAD -.144 .543 .071 .790 .866 .299 2.508 
Revasculari - -.567 .481 1.387 .239 .567 .221 1.457 
zation 
PVD -.071 .502 .020 .888 .931 .348 2.493 
Diastolic HF 1.013 .812 1.555 .212 2.753 .560 13.523 
Beta-blocker -1.207 .569 4.498 .034 .299 .098 .912 
usage 
ACE-I1ARBs .692 .877 .623 .430 1.998 .358 11.153 
usage 
ICD implanta- -.256 .550 .217 .641 .774 .263 2.276 
tion 
Telemonitoring .389 .437 .792 .373 1.475 .627 3.474 
aThe reference category is no change. bThe standard error of predictor variables in 
the model was far less than 2.0, indicating that there were no numerical problems 
with predictor variables in the final model. 
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Table 32 
Classification Accuracy of Predictors for Clinically Meaningful Change in 6MWD 
Predicted 
Observed Improved Deteriorated No change Percent correct 
Improved 44 4 20 64.7% 
Deteriorated 11 6 21 15.8% 
No change 20 3 52 69.3% 
Overall percentage 41.4% 7.2% 51.4% 56.4% 
history of diabetes, history of coronary artery disease, history of coronary 
revascularizations, history of peripheral vascular disease, diastolic HF, beta-blocker 
usage, ACE/ARBs usage, history of ICD implantation, and telemonitoring usage. 
Multinomial logistic regression analysis was performed by entering variables through an 
entry method into the main effects model. The category of participants with no 
meaningful change in 6MW was selected as the reference category. Multinomial 
regression analysis was performed on 161 participants (40 were missing data; see Table 
33). 
The benchmark to characterize this multinomial logistic regression model as 
useful was a 25% improvement over the rate of accuracy achievable by chance alone. 
The proportional by-chance accuracy rate was computed by calculating the proportion of 
cases for each group (improved, deteriorated, and no change) based on the number of 
cases in each group in the marginal percentages of case processing summary, as 
previously described, and then squaring and summing the proportion of cases in each 
group: 0.3422 + 0.1932 + 0.4662. The proportional by-chance accuracy criterion was 
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Table 33 
Case Processing Summary for Predictors of Clinically Meaningful Change in 6MW 
Marginal 
N Qercentage 
Clinically meaningful change in Improved 55 34.2% 
6MW Deteriorated 31 19.3% 
No change 75 46.6% 
DM-II Yes 67 41.6% 
No 94 58.4% 
History of CAD Yes 126 78.3% 
No 35 21.7% 
Revascularization procedures Yes 68 42.2% 
No 93 57.8% 
Peripheral vascular diseases Yes 41 25.5% 
No 120 74.5% 
Diastolic HF Yes 23 14.3% 
No 138 85.7% 
Beta-blockers Yes 131 81.4% 
No 30 18.6% 
ACE inhibitors/ARBs Yes 146 90.7% 
No 15 9.3% 
lCD Yes 45 28.0% 
No 116 72.0% 
Randomization Technology-driven disease 
72 44.7% 
management 
Standard medical care 89 55.3% 
Valid 161 100.0% 
Missing 40 
Total 201 
SUbpopulation 161 a 
aThe dependent variable has only one value observed in 161 (100.0%) subpopulations. 
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46.4% (1.25 x 37.1% = 46.4%). The classification accuracy rate of this model should be 
greater than the proportional by-chance accuracy criteria of 46.4%. 
The probability ofthe model's chi-square (X2 = 44.177, df= 24, 12 = 0.007) was 
statistically significant ill. < 0.05). The null hypothesis that there was no difference 
between the model without independent variables and the model with independent 
variables was rejected. The existence of a relationship between the independent variables 
and the dependent variable was supported (see Table 34). 
Table 34 
Model Fitting Information for Predictors of Clinically Meaningful Change in 6MW 
Model-fitting 
criteria Likelihood ratio tests 
-2 log 
Model likelihood Chi-square df Sig. 
Intercept only 334.875 
Final 290.698 44.177 24 .007 
The likelihood ratio tests for BMI, ejection fraction, beta-blocker usage, and ICD 
implantation were statistically significant (2 < 0.05), suggestive of significant prediction 
of clinically meaningful change in 6MW (see Table 35) BMI, LVEF, beta-blocker usage, 
and ICD implantation were significant predictors for differentiating clinically meaningful 
improvement in 6MW vs. no clinically meaningful change in 6MW, whereas beta-
blocker usage was the only variable significant enough to differentiate clinically 




Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in 6MW 
Model-fitting 
criteria Likelihood ratio tests 
-2 log 
likelihood of 
Effect reduced modela Chi-sguare df Sig. 
Intercept 2.907E2 .000 0 
Age 292.934 2.236 2 .327 
BMI 297.758 7.060 2 .029 
LVEF 298.792 8.094 2 .017 
DM-II 294.636 3.938 2 .140 
History of CAD 291.213 .515 2 .773 
History of 
294.878 4.180 2 .124 
revascularizations 
History of peripheral 
vascular disease 294.099 3.401 2 .183 
(PVD) 
Diastolic HF 293.209 2.511 2 .285 
Beta-blocker usage 297.250 6.551 2 .038 




7.671 2 .022 
Telemonitoring 291.581 .883 2 .643 
Note. The chi-square statistic was the difference in -2 log likelihoods between the final 
model and a reduced model. The reduced model was formed by omitting an effect from 
the final model. The null hypothesis was that all parameters ofthat effect were zero. 
aThis reduced model was equivalent to the final model because omitting the effect did not 
increase the degrees of freedom. 
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Table 36 
Parameter Estimates for Predictors of Clinically Meaningful Change in 6MW 
95% confidence 
interval for expb 
Clinically meaningful change in Lower Upper 
6MWa B SE Wald Sig. EXpb bound bound 
Improved Intercept 8.404 3.446 5.948 .015 
Age -.048 .033 2.150 .143 .953 .894 1.016 
BMI -.091 .043 4.426 .035 .913 .838 .994 
LVEF -.057 .021 7.473 .006 .945 .907 .984 
DM .741 .429 2.992 .084 2.098 .906 4.860 
CAD -.348 .520 .447 .504 .706 .255 1.957 
Revascularizations -.862 .450 3.671 .055 .422 .175 1.020 
PVD .047 .442 .011 .915 1.048 .441 2.493 
Diastolic HF 1.226 .889 1.901 .168 3.406 .597 19.445 
Beta-blocker usage -1.261 .577 4.773 .029 .283 .091 .878 
ACE-I1ARBs usage .058 .686 .007 .933 1.059 .276 4.061 
ICD implantation 1.117 .466 5.748 .017 3.057 1.226 7.619 
Telemonitoring -.062 .420 .022 .882 .940 .412 2.142 
Deteriorated Intercept 2.270 3.692 .378 .539 
Age -.026 .036 .496 .481 .975 .907 1.047 
BMI .024 .042 .333 .564 1.025 .943 1.113 
LVEF -.031 .024 1.734 .188 .969 .926 1.015 
DM -.145 .516 .079 .779 .865 .315 2.378 
CAD -.007 .617 .000 .991 .993 .296 3.330 
Revascularizations -.659 .535 1.519 .218 .517 .181 1.476 
PVD -1.005 .627 2.567 .109 .366 .107 1.252 
Diastolic HF 1.014 .883 1.318 .251 2.757 .488 15.567 
Beta-blocker usage -1.181 .596 3.928 .048 .307 .095 .987 
ACE-I1ARBs usage .331 .882 .140 .708 1.392 .247 7.842 
ICD implantation -.235 .635 .138 .711 .790 .228 2.742 
Telemonitoring .394 .479 .675 .411 1.483 .579 3.794 
aThe reference category is no change. bThe SE of predictor variables in the model was far less 
than 2.0, indicating that there were no numerical problems with predictor variables in the final 
model. 
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The classification accuracy for clinically meaningful improvement in 6MW was 
62% and for no meaningful change in 6MW, was 77%. The classification accuracy for 
clinically meaningful deterioration in 6MW was 23%. The overall prediction accuracy of 
this model was 62%, which was greater than that of classification accuracy by chance 
alone (i.e., 46.4%; see Table 37). Therefore, this prediction model was valid to predict 
clinically meaningful change in 6MW. 
Table 37 
Classification Accuracy for Predictors of Clinically Meaningful Change in 6MW 
Predicted 
Observed Improved Deteriorated No change Percent correct 
Improved 34 0 21 61.8% 
Deteriorated 5 7 19 22.6% 
No change 17 0 58 77.3% 
Overall percentage 34.8% 4.3% 60.9% 61.5% 
Predictors for Clinically Meaningful Change in MLHF Total Score 
Clinically relevant independent variables were selected from baseline 
characteristics to predict clinically meaningful change in MLHF total score. These 
variables included age, BMI, ejection fraction, history of diabetes, history of coronary 
artery disease, history of coronary revascularizations, history of peripheral vascular 
disease, diastolic HF, beta-blocker usage, ACE/ARBs usage, history oflCD implantation, 
and telemonitoring usage. Multinomial logistic regression analysis was performed by 
entering variables through an entry method into the main effects model. The category of 
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participants with no clinically meaningful change in MLHF total score was selected for 
the reference category. 
Multinomial regression analysis was performed on 181 participants (20 were 
missing data). The probability of chi-square statistic for the model with the variables was 
not statistically significant and did not meet the model-fitting criteria. The independent 
variables with low chi-square static values were dropped from the model, and the reduced 
model (meeting the fitting criteria) was deduced. The reduced model, using age, history 
of diabetes, history of coronary revascularization procedures, and telemonitoring and 
meeting the model-fitting criteria (X2= 16.34, df= 8,12 = 0.037) was performed on 201 
participants (none were missing data; see Table 38). 
The benchmark to characterize this multinomial logistic regression model as 
useful was a 25% improvement over the rate of accuracy achievable by chance alone. 
The proportional by-chance accuracy rate was computed by calculating the proportion of 
cases for each group (improved, deteriorated, and no change) based on the number of 
cases in each group in the marginal percentages of case processing summary, as 
previously described, and then squaring and summing the proportion of cases in each 
group: 0.2842 + 0.3382 + 0.3782. The proportional by-chance accuracy criterion was 
42.25% (1.25 x 33.79% = 42.25%). The classification accuracy rate ofthis model should 
be greater than the proportional by-chance accuracy criteria of 42.25% (see Table 39). 
Though the model fit well, there were no statistically significant individual predictors for 
clinically meaningful change in MLHF total score (see Tables 40 & 41). 
The classification accuracy for clinically meaningful improvement in MLHF total 
score was 23% and for no meaningful change in MLHF total score, was 58%. The 
105 
Table 38 




Clinically meaningful improved 57 28.4% 
change in MLHF total score deteriorated 68 33.8% 
no change 76 37.8% 
DM yes 85 42.3% 
no 116 57.7% 
Revascularization yes 86 42.8% 
procedures no 115 57.2% 
Randomization Technology driven disease 
95 47.3% 
management 
Standard medical care 106 52.7% 




aThe dependent variable had only one value observed in 93 (72.1 %) subpopulations. 
Table 39 
Model Fitting Information for Predictors of Clinically Meaningful Change in MLHF 
Total Score 
Model-fitting 
criteria Likelihood ratio tests 
-2 log 
Model likelihood Chi-square df Sig. 
Intercept only 360.376 
Final 343.992 16.384 8 .037 
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Table 40 
Likelihood Ratio Tests for Predictors of Clinically Meaningful Change in MLHF Total 
Score 
Model-fitting criteria Likelihood ratio tests 
-2 log likelihood of 
Effect reduced model Chi-square df Sig. 
Intercept 3.440E2 .000 0 
Age 349.117 5.125 2 .077 
DM 348.498 4.506 2 .105 
Telemonitoring 348.407 4.415 2 .110 
aThis reduced model was equivalent to the final model because omitting the effect did not 
increase the degrees of freedom. 
Table 41 
Parameter Estimates for Predictors of Clinically Meaningful Change in MLHF Total 
Score 
95% confidence 
interval for expb 
Clinically meaningful change Lower Upper 
in MLHF total scorea B SE Wald Sig. Expb bound bound 
Improved Intercept -1.950 1.975 .975 .323 
Age .018 .025 .496 .481 1.018 .969 1.069 
Diabetes mellitus .640 .368 3.030 .082 1.897 .923 3.899 
Revascularization -.319 .366 .761 .383 .727 .355 1.488 
Telemonitoring .417 .365 1.304 .254 1.517 .742 3.100 
Deterior- Intercept 2.459 1.764 1.944 .163 
ated Age -.035 .023 2.330 .127 .966 .924 1.010 
Diabetes mellitus -.101 .361 .078 .780 .904 .445 1.835 
Revascularization -.691 .358 3.736 .053 .501 .248 1.010 
T elemonitoring .729 .353 4.276 .039 2.073 1.039 4.138 




Classification Accuracy for Predictors of Clinically Meaningful Change in MLHF Total 
Score 
Predicted 
Observed Improved Deteriorated No change Percent correct 
Improved 13 14 30 22.8% 
Deteriorated 8 29 31 42.6% 
No change 14 18 44 57.9% 
Overall percentage 17.4% 30.3% 52.2% 42.8% 
classification accuracy for clinically meaningful deterioration in MLHF total score was 
43%. The overall prediction accuracy of this model was 42.8%, which was greater than 
that of classification accuracy by chance alone (i.e., 42.28%; see Table 42). Therefore, 
this prediction model was valid to predict clinically meaningful change in MLHF total 
score. 
Clinical Outcomes 
Technology-driven HF management was shown to reduce the number of days of 
hospitalization from HF as the primary diagnosis, the number of days of hospitalization 
from other cardiovascular causes, the number of Medicare claims for inpatient 
admissions, the number deaths from all causes, the number of deaths from all 
cardiovascular causes, and the number of deaths from HF, compared to standard care. 
However, these differences were not statistically significant. Technology-driven HF 
management showed increases in the number of days of hospitalizations from 
noncardiovascular causes, number of ER visits, number of clinic visits for all causes, 
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number of clinical visits for all cardiovascular causes, and number of clinical visits from 
HF ill < 0.05) and increased cost of clinic claims (12 < 0.05). 
Therefore, technology-driven HF management reduced the number of days of 
hospitalization but increased the number of outpatient visits for all cardiovascular causes 
or HF. The standard care group had a higher number of days of hospitalization and a 
lower number of outpatient visits from cardiovascular causes or HF. Further analysis by 
combining these end points and deducing cost effectiveness was beyond the scope of this 
dissertation. The primary end points of the HCFA Demonstration Project were separately 
analyzed by primary investigators of the project (see Table 43). 
Mortality 
Out of201 total patients who were included in final analysis, 6 out of95 (6.3%) 
in the technology-driven HF management group and 10 out of 106 (9.4%) in the standard 
care group died from any cause (OR: 0.647,95%; CI: 0.226-1.854). In terms of 
cardiovascular deaths, 5 out of95 (5.3%) in the technology-driven HF management 
group and 9 out of 106 (8.5%) in the standard care group died from cardiovascular causes 
(OR: 0.599,95%; CI: 0.193-1.854). Finally, 3 out of95 (3.2%) patients in the 
technology-driven HF management group and 5 out of 106 (4.7%) in the standard care 
group died from HF (OR: 0.659,95%; CI: 0.153-2.833). Technology-driven HF 
management showed a trend toward decreasing all causes of mortality, mortality from all 
cardiovascular causes, and mortality from worsening ofHF (see Figures 11-13). 
However, the incremental impact of adding a telemonitoring system to the standard of 
care was not statistically significant (p> 0.05). 
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Table 43 
Clinical End Points for Technology-Driven Management GrouQ vs. Standard Care GrouQ 
Treatment group Control group !-test 
N Sum Mean N Sum Q: 
Mean value 
Days of hospitalization (all 95 358 3.77 106 263 2.48 0.30 
causes) 
Days ofhospitaiization (CHF 95 116 1.22 106 158 1.49 0.69 
primary diagnosis) 
Days of hospitalization 95 172 1.81 106 195 1.84 0.97 
(other CVD primary 
diagnosis) 
Days of hospitalization 95 186 1.96 106 68 0.64 0.78 
(noncardiovascular primary 
diagnosis) 
In-patient claims 95 68 0.72 106 90 0.85 0.41 
ER claims 95 37 0.39 106 25 0.24 0.10 
Clinic visits (all causes) 95 290 3.05 106 87 0.82 0.00 
Clinic visits (CHF primary 95 81 0.85 106 21 0.20 0.01 
diagnosis) 
Clinic visits (CVD primary 95 176 1.85 106 45 0.42 0.00 
diagnosis) 
Deaths from all causes 95 6 0.06 106 10 0.09 0.41 
Deaths from all 95 5 0.05 106 9 0.08 0.36 
cardiovascular causes 
Deaths from HF 95 3 0.03 106 5 0.05 0.57 
Cost of in-patient claims 95 620769 6534 106 675596 6373 0.93 
Cost of ER claims 95 7437 78 106 7882 74 0.89 
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Summary of Results 
This sub study was conducted based on a multicentered, randomized, phase III 
clinical trial of Medicare beneficiaries who were previously hospitalized with HF 
(NYHA Class II-IV) to evaluate the combined clinical and economic outcomes of 
adding a technology-driven HF monitoring system to standard HF management. The 
effect of technology-driven HF monitoring on functional capacity and QOL was 
evaluated by measuring the magnitude and direction of change at a 6-month follow-up. 
Traditional statistical techniques were translated to derive novel refined methods in order 
to define clinically meaningful difference in terms of functional capacity and QOL. The 
agreement between existing objective methods of assessing severity ofHF in terms of 
NYHA class and 6MWD was tested. The clinically relevant factors predictive of 
clinically meaningful change in functional capacity and QOL were also deduced. Finally, 
the clinical outcomes of technology-driven HF management vs. standard care groups at 
the end of 6 months were compared. 
Importance of Clinically Meaningful Change 
Traditionally, treatment effects are evaluated by comparing changes resulting 
from the treatments under investigation and evaluating the statistical significance of that 
difference. In clinical trials, treatment effects often show statistically significant 
difference, but very little attention is paid to clinical significance. Statistical significance 
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is a function of the alpha level, the variance of the outcome measure, the 
magnitude of the difference, and the sample size. Clinicians often are interested in the 
variability of responses between and within groups. However, traditional methods are 
very limited in terms of determining the variability of response within a group due to lack 
of translation of traditional statistical methods to precise and refined novel statistical 
methods for determining clinically meaningful difference. 
Need for Adjustment of Regression to the Mean 
If patients, particularly those with extreme values, are repeatedly measured after 
treatment, the repeat measurement will be closer to the mean of the whole population 
than the initial measures were. In clinical trials, this phenomenon is often interpreted as 
showing the effect of the intervention or treatment; clinical investigators often assume 
that ifthey observe differences in baseline measurements among subjects, they can take 
the difference between the pre- and post-intervention/treatment values as the outcome 
value. However, it is incorrect to do so because imbalances at the baseline values will be 
reversed due to RTM. For example, subjects with a low degree of impairment at baseline 
will show less improvement, and subjects with a higher degree of impairment at baseline 
will show greater improvement. 
In this study, functional capacity and QOL were repeatedly measured in terms of 
6MWD or 6MW and MLHF scores on same subjects before and after treatment. At a 6-
month follow-up, it was found that RTM was statistically significant, which meant that 
natural variation due to repeat data collection gave the appearance of real change. Hence, 
in clinical trials, if functional capacity or QOL is measured pre and post test, RTM must 
be estimated; otherwise, treatment effects will be overestimated and biased. If R TM is 
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significant, then RTM should be adjusted using the E-N method to determine true change 
from baseline. 
Clinically Meaningful Change in Functional Capacity and Quality of Life 
In this study, clinically meaningful difference in functional capacity and QOL was 
estimated after a 6-month follow-up after adjusting for RTM effects. The change in 
functional capacity in terms of6MWD by 42 m (39 m-42 m) or 6MW by 3668 kg/m 
(3063 kg/m-3820 kg/m) and in QOL in terms ofMLHF total score by 6.0 (5.0-7.0), 
physical dimension score by 4.0 (3.0-4.0), and emotional dimension score by 2.0 (2.0-
3.0) from baseline was determined as either clinically meaningful improvement or 
deterioration. 
Effect of Technology-Driven Heart Failure Management on Functional Capacity 
Addition oftwice-daily home telemonitoring of weight and HF symptoms to 
standard care for Medicare beneficiaries with chronic HF did not result in clinically 
meaningful change in functional capacity after 6 months. The null hypothesis failed to be 
rejected and the alternative hypothesis failed to be accepted. After stratification by 
NYHA class, it was found that technology-driven HF management retarded the change 
from baseline for a slightly higher proportion of patients in NYHA Class II than in 
Classes III and IV; a slightly higher proportion of patients in NYHA Classes III and IV 
than in Class II showed clinically meaningful improvement. In the standard care group, a 
slightly higher proportion of patients in NYHA Class II showed improvement and a 
slightly higher proportion of patients in Classes III and IV showed retarded change. 
Therefore, technology-driven HF management improved functional capacity for a slightly 
higher proportion of patients in NYHA Classes III and IV and stabilized functional 
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capacity for a slightly higher proportion of patients in NYHA Class II. However, none of 
these effects reached statistical significance at a 6-month follow-up. Therefore, there is 
no clinically meaningful incremental benefit in functional capacity from adding 
technology-driven HF monitoring to standard care. 
Effect of Technology-Driven Heart Failure Management on Quality of Life 
Addition of twice-daily home telemonitoring of weight and HF symptoms to 
standard care for Medicare beneficiaries with chronic HF did not show clinically 
meaningful change in QOL. The null hypothesis failed to be rejected, and the alternative 
hypothesis failed to be accepted. The standard care group showed retarded change, and 
the technology-driven HF management group showed clinically meaningful deterioration 
in a greater proportion of patients than the standard care group. After stratification by 
NYHA class, these trends persisted irrespective of NYHA class. However, none of these 
effects reached statistical significance. Therefore, there is no clinically meaningful 
benefit in QOL from adding technology-driven HF monitoring to standard care. Rather, 
technology-driven HF monitoring may be counterproductive and lead to deterioration in 
QOL, possibly by interfering with the daily routine of patients. Hence, patients may 
perceive technology-driven HF monitoring as impairing their QOL. 
Effect of Technology-Driven Heart Failure Management on Clinical Outcomes 
Technology-driven HF management did not show any statistically significant 
benefit for reducing the number of Medicare claims for inpatient admissions; the number 
of days of hospitalization from HF and other cardiovascular causes; and the number of 
deaths from all causes, all cardiovascular causes, and HF at the end of a 6-month follow-
up. However, there was a statistically significant increase in the number of outpatient 
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clinic visits for all causes, all cardiovascular causes, and HF and the cost of Medicare 
claims for clinic visits at a 6-month follow-up. After 6 months, technology-driven HF 
management significantly increased resource utilization of outpatient care, and there was 
no statistically significant reduction in resource utilization of inpatient care when 
compared to standard care. 
The intervention group received twice-daily monitoring of weight and symptoms 
by telemonitoring center nurses, which could have led to sending alerts to physicians 
early in the course of HF decompensation. A substantial proportion of the participants 
(25%) reported receiving care from a primary care physician without a cardiologist on 
board. In addition, the cardiologists who provided care to the participants may not have 
had training in advanced HF management. For these reasons, patients may have 
overutilized outpatient clinic visits. Participants in the standard care group did not report 
this type of communication between physician and patient, probably because the 
progression of the disease was recognized in the later part of decompensation process. 
Therefore, this group experienced more hospitalizations and total days of 
hospitalizations; however, these effects didn't reach statistical significance. At the same 
time, the standard care group experienced a statistically significant reduction in outpatient 
clinic visits at the end of 6 months compared to the technology-driven HF management 
group. 
Agreement Between Objective Assessment of Functional Capacity and Classification of 
Heart Failure NYHA Criteria 
To determine a patient's NYHA class, clinicians ask patients about their HF 
symptoms and the effect on exertion (i.e., how far they can walk before symptom onset). 
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However, there is no consistent method for determining NYHA functional class. The 
method of assessing NYHA class is arbitrary, and intraoperator variability is 66% (R. 
Claire et al., 2007). As mentioned earlier, 6MWD is a simple, cost-effective means of 
clinically assessing the functional capacity of patients with cardiac and pulmonary 
diseases. The NYHA system and 6MWD are regularly used as outcome measures in 
clinical trials and are even included in HF management guidelines ("ACC/AHA 
Guidelines," 2009). Hence, the agreement between these two functional classifications 
was examined. 
There is a lack of agreement between objective assessment of NYHA functional 
class and objective measurement of functional capacity (6MWD). The correlation 
coefficient between these two outcome measures was very poor because either patients 
are under- or over-reporting functional capacity to their physicians or physicians are 
misinterpreting patient class compared to objectively measured values. Still, 6MWD 
may not be the single best indicator of severity of HF among groups of patients of 
different ages, genders, BMIs, and comorbid conditions. This lack of consistency 
between NYHA class and 6MWD suggests the need to develop novel classification 
methods by designing norm-referenced equations comprising age, gender, BMI, 
comorbid conditions, and symptoms and signs of HF. 
Prediction of Change in Quality of Life by Change in Functional Capacity 
In this study, change refers to clinically meaningful change, not statistical change 
from baseline. The sensitivity and specificity of change in functional capacity to predict 
change in QOL was low, and Spearman correlation coefficients were very weak. 
Clinically meaningful improvement in functional capacity to predict clinically 
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meaningful improvement in QOL and clinically meaningful deterioration in functional 
capacity to predict clinically meaningful deterioration in QOL, and vice versa, were 
estimated. If there was improvement in functional capacity (6MWD), the probability of 
improvement in QOL (MLHF) was 56%. However, if there was improvement in QOL, 
the probability of improvement in functional capacity was only 44%. If there was 
deterioration in functional capacity, the probability of deterioration in QOL was 35%. 
However, ifthere was deterioration in QOL, the probability of deterioration in functional 
capacity was 55%. 
The probability of change in functional capacity was more responsive to 
deterioration in QOL than probability of improvement in QOL: If there was no change in 
functional capacity, the probability of no change in QOL was 35%. If there was no 
change in QOL, the probability of no change in functional capacity was 31%. If the 
functional capacity was measured in terms of 6MW, it had similar probabilities of 
predicting improvement and deterioration patterns. But, if there was no change in 
functional capacity, the probability of no change in QOL was 53%. Ifthere was no 
change in QOL, the probability of no change in functional capacity was 43%, which was 
8% higher than that of no change in 6MWD. 
Overall, the change in functional capacity is not a good predictor of similar 
directional change in QOL and vice versa. Therefore, if a clinician sees improvement in 
functional capacity, the probability of improvement in QOL is 56%. If there is 
deterioration in QOL, the probability of deterioration in functional capacity is 55%. In all 
other cases, it is difficult to predict the direction of change in QOL with respect to change 
in functional capacity and vice versa. 
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Predictors of Change in Physical and Emotional Dimension Scores by Change in 
Functional Capacity 
Ifthere is change in functional capacity (6MWD), the probability of similar 
directional change in physical dimension score is 69% for improvement, 35% for 
deterioration, and 46% for no change; the probability of similar directional change in 
emotional dimension score is 100% for improvement, 64% for deterioration, and 45% for 
no change. If there is a change in physical dimension score, the probability of similar 
directional change in functional capacity is 30% for improvement, 31 % for deterioration, 
and 71 % for no change. If there is a change in emotional dimension score, the 
probability of similar directional change in functional capacity is 12% for improvement, 
17% for deterioration, and 95% for no change. 
In summary, change in functional capacity is a poor predictor of change in total 
QOL; however, functional capacity shows good predictive patterns for change in physical 
and emotional components of QOL. Improvement in functional capacity increases the 
probability of improvement in physical dimension score but not vice versa. Change in 
functional capacity increases the probability of similar directional change in emotional 
dimension score but not vice versa. Surprisingly, change in functional capacity better 
predicts change in emotional dimension score than physical dimension score. Similar 
patterns were observed with 6MW. It is not surprising that improvement in functional 
capacity predicts improvement in physical dimension score. Surprisingly emotional 
scores are influenced by physical endurance. The sense of accomplishment in improving 
functional capacity may improve patients' self esteem by providing them with positive 
feedback, which in tum improves the emotional dimension score. 
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Perception of QOL involves a complex interplay of multidimensional indices of 
life. A change in physical, emotional, or socioeconomic indices that leads to a change in 
the suhscore of one dimension does not always translate into change in total score or 
functional capacity due to fluctuations in other item scores. Therefore, change in 
functional capacity is a poor predictor of change in total QOL score and vice versa. 
Specificity and negative predictive value of change in functional capacity are far better 
than sensitivity and positive predictive values to predict similar directional change in total 
QOL and its components. 
Predictors of Clinically Meaningful Change for Functional Capacity 
BMI, LVEF, type-2 diabetes, and beta-blocker usage are statistically significant 
predictors of clinically meaningful change in functional capacity (6MWD). BMI and 
L VEF are inversely related to improvement in functional capacity (i.e., the regression 
coefficients are negative). As BMI increases, improvement in functional capacity is less 
likely. As LVEF improves, functional capacity improves initially; once functional 
capacity reaches the ceiling effect, improvement in functional capacity is less likely. 
Subjects with type 2 diabetes mellitus (OR 2.281,95% ofCI: 1.019 to 5.103) are 
more likely to improve in functional capacity. Diabetes itself doesn't improve functional 
capacity, but additional diabetics-related care processes might contribute to improvement 
in functional capacity. Subjects who use beta-blockers (OR 0.289, 95% of CI: 0.094 to 
0.888) are less likely to show improvement and less likely to show deterioration (OR 
0.299,95% ofCI: 0.98 to 0.912) in functional capacity. Therefore, beta-blockers playa 
significant role in stabilizing functional capacity. 
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BMI, L VEF, and beta-blocker usage show similar significant predictive patterns 
for predicting clinically meaningful change in 6MW. ICD implantation is also a 
significant predictor of functional capacity (6MW). Subjects with ICD implantation 
show clinically meaningful improvement in functional capacity (OR 3.06, 95% of CI: 
1.23 to 2.14). 
Predictors of Change in Quality of Life 
The reduced regression model, which contained the independent variables of age, 
type 2 diabetes mellitus, revascularization procedures, and technology-driven HF 
monitoring, satisfied model fit criteria. None of the independent variables surfaced as 
significant individual predictors of clinically meaningful improvement in QOL (MLHF 
score), whereas technology-driven HF monitoring was a statistically significant predictor 
of clinically meaningful deterioration in QOL. Twice-daily recording of weight, 
answering automated questions about symptoms, and receiving telephone calls from 
Alere nurses may interfere with the daily routines of patients with HF, who may perceive 
technology-driven HF monitoring as impairing their QOL. 
Comparison of Existing Studies 
It has to be acknowledged that to date the majority of studies that test telephonic 
support (Riegel et aI, 2002; Laramee, 2003; DeBusk, Miller and Parker, 2004; Gesica 
Inv, 2005; Riegel et aI, 2005) and vital sign monitoring (deLusignan, 2001; Woodend et 
aI, 2003; Capomolla et aI, 2004) have not shown a mortality benefit in patients with 
chronic heart failure. Only a few studies have shown that telephonic support (Cleland et 
aI, 2005) and vital sign monitoring (Cleland et aI, 2005; Goldberg et aI, 2002) reduced 
mortality. The difference in mix of patients and provider populations, geographical 
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settings, treatment modalities, and monitoring strategies might explain different outcomes 
in different studies. 
Telephonic support and vital sign monitoring are two different strategies to 
monitor HF patients. Cleland (2005) and Goldberg (2002) showed there was a significant 
absolute reduction in mortality by 10.4% and 16% respectively through electronic 
monitoring of vital signs and symptoms. In our study the absolute reduction in mortality 
was only 3% which is not statistically significant. In Cleland's (2005) study primary care 
physicians delivered standard care for all heart failure patients. In the WHARF 
(Goldberg et aI, 2002) trial, patients were sicker with more advanced heart failure 
(NYHA class III and IV) than in our sample and care was provided by cardiologists with 
advanced training in heart failure management. In our study 31 % of patients were NYHA 
class II and a substantial proportion of patient care was provided by cardiologists without 
advanced training in heart failure or by primary care physicians without a cardiologist on 
board. However, the proportion of patients on beta-blockers and ACE-I1ARBs in our 
study was greater than in the WHARF trial (Goldberg et aI, 2002) suggesting more 
widespread acceptance of the American College of Cardiology and the American Heart 
Association guidelines. Our study'S patient population having less advanced heart failure 
would predict much lower mortality than observed in the WHARF trial and hence less 
opportunity for electronic monitoring to reduce the absolute death rate. 
Strengths of the Study 
The WHARF trial (Goldberg et aI., 2002) was the first multi-centered, prospective 
trial conducted for patients with advanced HF (NYHA Classes III and IV). Researchers 
concluded that there was a significant mortality benefit from home-based telemonitoring 
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with a nurse-staffed call center (Goldberg et aI., 2002). At the end of 6 months, 18.4% of 
participants in the standard care group and 8.0% of those in the telemonitored group died 
(Goldberg et aI., 2002). Thus, there was a 56.2% relative risk reduction in mortality for 
the telemonitored group of patients with advanced HF (Goldberg et al., 2002). However, 
there was no significant difference between the two groups with respect to length of stay, 
number of hospitalizations, and utilization of resources (Goldberg et aI., 2002). 
The results of the WHARF study were attributable to patients with advanced HF 
(NYHA Classes III and IV) but not to NYHA Class II patients because the study was 
conducted for NYHA class III and IV patients only (Goldberg et aI., 2002). Only 
cardiologists with special training in advanced HF management provided care for patients 
recruited for the study (Goldberg et aI., 2002). It is possible that these cardiologists better 
utilized the data generated through technology-driven HF monitoring than primary care 
physicians would have. Hence, reproducing a similar benefit in a real-world clinical 
setting may not be feasible because most HF care is provided by cardiologists without 
training in advanced HF management and primary care physicians without training in 
cardiology or without a cardiologist on board. 
The HCF A HF Demonstration Project was conducted for Medicare beneficiaries 
classified as NYHA Class II-IV. Therefore, the findings of the sub-study are attributable 
to elderly patients with HF who belong to NYHA Class II-IV. HF management was 
provided by cardiologists with or without training in advanced HF management or by 
primary care physicians with or without cardiologist on board. Therefore, the findings of 
the sub-study are attributable to the current real-world clinical setting of HF management. 
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In the WHARF trial, due to differential drop-outs between groups (including 
death and drop-outs), the baseline QOL scores were carried forward to compare scores 
for all patients at 6 months, which might have introduced statistical bias (Goldberg et aI., 
2002). In the current study, patients who dropped out were excluded from the analysis 
and were compared with participants who were included in the analysis. Patients who 
died from HF or cardiovascular causes were included in the clinically meaningful 
deterioration group and given extremely worsened scores of QOL and functional capacity 
to minimize bias. 
Other HF monitoring studies have used traditional distribution-based statistical 
methods and placed importance on statistical significance rather than clinical significance 
(Goldberg et aI., 2002). The current study addressed the importance ofRTM and 
adjusted R TM while measuring true change from the baseline. Also, the importance of 
measuring clinically meaningful change from the baseline, instead of using traditional 
methods of assessing statistically significant difference, was addressed. Traditional 
statistics were translated into more refined methods to provide meaningful information to 
clinicians on the effect of technology-driven HF management vs. standard care on 
functional capacity and QOL of patients with HF, clinically meaningful change, and 
factors affecting the degree of change and direction of change at the end of 6 months. 
Limitations of the Study 
The study was conducted for Medicare beneficiaries over 65 who were 
hospitalized for HF less than 1 year ago (i.e., NYHA Class II-IV). Therefore, the 
findings may not be attributable to patients with HF who are younger than 65. Patients 
were randomized from four geographic and hospital settings. The findings may not be 
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attributable to other centers where HF care is provided primarily by cardiologists, 
especially those with special training in advanced HF management. 
Because a substantial proportion of patients (~25%) did not have a cardiologist on 
board and primary care physicians provided all of their HF management, there was 
overutilization of services and less efficient utilization of HF monitoring alerts. 
Physicians and patients were not blinded to the technology-driven HF monitoring system; 
hence, there was a likelihood of introducing treatment bias. Drop-outs, lost-to-follow 
cases, and missing data were unexpectedly high, and the compliance rate was low. The 
sub study was limited to a 6-month follow-up. Hence, the long-term effects of 
technology-driven HF monitoring are not known. 
Post-Hoc Power Analysis 
Post-hoc power is directly proportional to the effect size and inversely 
proportional to the 12-value. Ifthe effect size is trivial or the 12-value is large, then the 
post-hoc power will be low. If the 12-value is larger than 0.05, then the post-hoc power is 
likely to be less than 50%. Therefore, calculation of the 12-value is not meaningful in the 
case of a negative clinical trial. Several authors have mentioned the inappropriateness of 
post-hoc power for negative end points and have suggested the use of confidence 
intervals instead of post-hoc power (Detsky & Sackett, 1985; Goodman & Berlin, 1994; 
Smith & Bates, 1992). Post-hoc power can provide meaningful information for positive 
end points (Detsky & Sackett, 1985; Goodman & Berlin, 1994; Smith & Bates, 1992). 
In this study of change in functional capacity and QOL, there was no statistically 
significant clinically meaningful difference between the telemonitored vs. standard care 
groups. Based on the direction of change in functional capacity and QOL, the sample 
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was grouped into three groups: clinically meaningful improvement, deterioration, and no 
change. Confidence intervals for X2 static for above frequency distributions were 
calculated. The 95% confidence interval for the Chi-squared distribution with two 
degrees of freedom was 0.05-7.38. Chi-square statistics for distributions for clinically 
meaningful change in 6MWD (0.256), 6MW (0.131), MLHF score (3.877), physical 
dimension score (0.309), and emotional domain score (0.762) for the treatment vs. 
standard care group fell inside the 95% confidence interval. 
Post-hoc power analysis was performed for multinomial logistic regression 
models and other clinical outcomes with statistical significance. Post-hoc power of the 
prediction model to predict clinically meaningful change in functional capacity measured 
in terms of6MWD (alpha = 0.05, number of predictors in the model = 12, R2= 0.236, 
valid sample size = 181) and 6MW (alpha = 0.05, number of predictors in the model = 
12, R2= 0.240, valid sample size = 161) was 99.9%. Post-hoc power of the model to 
predict clinically meaningful change in QOL measured in terms ofMLHF score (alpha = 
0.05, number of predictors in the model = 4, R2= 0.201, valid sample size = 201) was 
92%. Post-hoc power to detect mean difference between the telemonitored vs. standard 
care groups for the number of clinic visits for all causes, for HF, and for other 
cardiovascular causes was 97%, 65%, and 95%, respectively. The post-hoc power to 
detect mean difference in cost of clinic claims (treatment group vs. standard care group) 
was 65%. Other well-powered studies are needed to further investigate underpowered 
clinical endpoints. 
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Conclusions and Implications 
1. Both the technology-driven HF management and standard care groups showed 
significant improvement in functional capacity and QOL from baseline after 6 
months. However, the differences between groups were not statistically 
significant. Therefore, there is no meaningful benefit in terms of functional 
capacity and QOL from the addition of home telemonitoring systems to standard 
care. In fact, home telemonitoring systems may deteriorate QOL by interfering 
with patients' daily routine activities. In addition, there was a statistically 
significant increase in the total number of clinic visits, the number of clinic visits 
for HF, and the number of visits for other cardiovascular causes. In turn, there 
was a statistically significant increase in the cost of clinic (Medicare) claims. 
2. In clinical trials, if outcomes are measured pre and post test, RTM must be 
estimated; otherwise, treatment effects will be overestimated and biased. If R TM 
is significant, then it should be adjusted to determine true change from baseline. 
3. In clinical trials, investigators should focus on measuring clinically meaningful 
treatment effects rather than statistically significant difference. In this study, 
clinically meaningful change in functional capacity and QOL were defined 
according to often-used outcome measures in HF research. The change in 
functional capacity in terms of6MWD by 42 meters (39 m-42 m) or 6MW by 
3668 kg/m (3063 kg/m-3820 kg/m) and QOL in terms ofMLHF total score by 
6.0 (5.0-7.0), physical dimension score by 4.0 (3.0-4.0), emotional dimension 
score by 2.0 (2.0-3.0) from baseline were determined to be either clinically 
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meaningful improvement or deterioration based on the direction of change for 
elderly patients with chronic HF. 
4. Change in functional capacity is a good predictor of change in emotional 
dimension score and a fair predictor of change in physical dimension score but 
not predictive of change in overall QOL. If clinicians target improvement in 
functional capacity, they can improve the emotional component and, to a fair 
extent, the physical component, but not vice versa. Striving for clinically 
meaningful improvement in functional capacity may be a clinically meaningful 
strategy for dealing with depression in patients with chronic HF. 
5. BMI, LVEF, beta-blocker usage, and ICD implantation are the best clinically 
relevant predictors of change in functional capacity. Strategies should be targeted 
to decrease BM! and improve cardiac index, rather than focusing on L VEF to 
improve functional capacity. Beta-blockers stabilize functional capacity, and ICD 
implantation improves functional capacity. There are no best predictors of 
improvement in QOL. 
6. There is a lack of agreement between objective assessment ofNYHA functional 
class and objective measurement of functional capacity (6MWD). The correlation 
coefficient between these two outcome measures is very poor. Utilization of 
NYHA class change as an outcome measure in clinical trials for measuring 
treatment effect may lead to over- or under-estimation. 
Future Directives for Research 
Due to lack of consistency and a high degree of operator variability when 
classifying patients with HF using the NYHA method, there is an imminent need for 
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development of novel classification methods by designing norm-referenced equations 
comprising clinical parameters predictive of cardiac function or index. More explorative 
research should be performed to identify diabetic care processes that might show 
clinically meaningful improvement in functional capacity for the diabetic subset of 
patients with HF. More aggressive and frequent monitoring of patients appears to be 
counterproductive and to lead to noncompliance, frequent drop-outs, and loss to follow 
up. 
Call center nurses were not authorized to independently optimize medications, 
even in consultation with a cardiologist or primary care physician. Therefore, instead of 
twice-daily monitoring by call center nurses, less frequent home monitoring by healthcare 
personnel trained in cardiology who are authorized to perform optimization/adjustment of 
medications either independently or in consultation with a cardiologist might lead to 
better resource utilization and reduction ofER visits, outpatient clinic visits, and inpatient 
hospitalizations. On the other hand, if standard of care is provided while adhering to HF 
guidelines and closely monitoring HF clinic follow-ups, then there may not be room for 
further clinically meaningful benefit through home telemonitoring. 
Analysis of combined clinical endpoints and costs should be performed to 
determine the benefits of technology-driven HF management and HF monitoring 
strategies. Further analysis should be conducted to evaluate efficient utilization of 
information gathered through technology-driven HF monitoring and subsequent resource 
utilization by primary care physicians vs. cardiologists with and without advanced 
training in HF in providing HF care. 
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ACE-I: Angiotensin converting enzyme inhibitors, a class of medications that 
inhibit angiotensin converting enzyme 
Angina: Angina is chest pain that is due to an inadequate supply of oxygen to the 
heart muscle 
Beta-blockers: A class of medications that block beta-adrenergic substances such 
as adrenaline (epinephrine), a key agent in the "sympathetic" portion of the autonomic 
nervous system and activation of the heart muscle 
Blood Pressure: Pressure of the blood within the arteries 
BUN: Blood urea nitrogen, measures primarily the urea level in blood 
Clinic visit: Refers to outpatient care at physician's office 
Cohort: In a clinical trial, a group of study subjects or patients 
Congestive Heart Failure: A condition in which the heart's function as a pump 
is inadequate to meet the body's needs 
Coronary Angiography: Accurate method for evaluating and defining coronary 
artery disease (CAD) 
1. Adapted from HCFA Heart Failure Demonstration Project protocol, pp. 71-77. 
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Creatinine: Creatinine is produced from creatine, a molecule of major 
importance for energy production in muscles 
Death due to Non-cardiovascular causes: Death not due to any cardiac or 
vascular events 
Death due to Progressive Heart Failure: Death preceded by worsening signs 
and symptoms of heart failure and/or circulatory collapse due to pump failure in the 
absence of acute myocardial infarction 
Death due to other Cardiac Causes including Vascular Causes: Death due to 
other cardiac causes, such as non-sudden arrhythmic death, due to vascular events such as 
stroke, pulmonary embolus, ruptured aneurysm, etc. 
Diastolic Dysfunction: Abnormal relaxation pattern of the left ventricle 
Echocardiography: A diagnostic test, which uses ultrasound waves to make 
images of heart muscles, valves and other internal structures. It measures the function of 
heart and its structures 
Ejection Fraction: The proportion of blood that is pumped out of a filled 
ventricle with each heart beat 
Emergency room visit (ER): Refers to outpatient care at emergency room, not 
considered as hospitalization 
Fatal Myocardial Infarction: Death as a result of an autopsy - verified 
myocardial infarction or death before hospital discharge from a hospital - verified acute 
myocardial infarction 
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HCFA: The health care finance administration, the part ofthe US Department of 
Health and Human Services (HHS) that is responsible for administering Medicare and 
Medicaid 
Hospitalization: Refers to inpatient admission to hospital, either overnight stay 
or prolonged stay 
Functional Capacity: Functional capacity refers to the performance of, or the 
capacity to perform, regular daily activities 
Morbidity: Illness or disease 
Mortality: It refers to a fatal outcome, death 
Quality of Life: A state of complete physical, mental, and social well-being and 
not merely the absence of disease or infirmity 
Six Minute Walk Distance: Distance that a patient can quickly walk on a flat, 
hard surface in a period of 6 minutes 
Six Minute Work: The product of 6-minute walk distance multiplied by the 
weight of the patient: 6-min walk distance (in meters) x body weight (in kilograms) 
Sudden Cardiac Death: Death, or irreversible deterioration leading to death, 
occurring without warning or within one hour of symptoms (unless it is the result of 
circulatory collapse due to pump failure or fatal myocardial infarction or other well 
defines cardiac, vascular or non-cardiac causes. Sudden cardiac death will be further 
categorized as due to brady-arrythmia, ventricular tachycardia, ventricular fibrillation, 
electromechanical dissociation, or unknown cause of death 
Systolic Dysfunction: Impairment of forward pumping function of the heart 
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